



The long-term effects of occupational exposure to vinyl chloride monomer on microcirculation: a cross-sectional study 15 years after retirement

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002785
Article Type:	Research
Date Submitted by the Author:	27-Feb-2013
Complete List of Authors:	Lopez, Vincent; CHU G. Montpied, Chamoux, Alain; CHU G. Montpied, Tempier, Marion; CHU G. Montpied, Thiel, Helene; CHU G. Montpied, Ughetto, Sylvie; CHU G. Montpied, Trousselard, Marion; IRBA, Naughton, Geraldine; Australian Catholic University, School of Exercise Science Dutheil, Frederic; CHU G. Montpied,
Primary Subject Heading:	Occupational and environmental medicine
Secondary Subject Heading:	Public health
Keywords:	OCCUPATIONAL & INDUSTRIAL MEDICINE, CHEMICAL PATHOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

only

1
2
3 **The long-term effects of occupational exposure to vinyl chloride monomer**
4
5 **on microcirculation: a cross-sectional study 15 years after retirement**
6
7
8
9

10
11
12
13 Vincent Lopez ¹, Alain Chamoux ¹, Marion Tempier ², Hélène Thiel ³, Sylvie Ughetto ⁴,
14
15 Marion Trousselard ⁵, Geraldine Naughton ⁶, Frédéric Dutheil ^{1,6,7,*}
16
17

18
19
20 ¹ Occupational Medicine, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand,
21
22 France

23
24 ² Radiopharmacy, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand, France

25
26 ³ Vascular Medicine, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand,
27
28 France

29
30
31 ⁴ Department of Medical Information - Clinical research and innovation direction, University
32
33 Hospital CHU G. Montpied, 63000 Clermont-Ferrand, France

34
35 ⁵ Neurophysiology of emotions, ENOP department, CRSSA/IRBA, 38702 La Tronche,
36
37 France

38
39
40 ⁶ School of Exercise Science, Australian Catholic University, Locked Bag 4115 Fitzroy MDC
41
42 VIC 3065, Australia

43
44 ⁷ Laboratory of Metabolic Adaptations to Exercise in Physiological and Pathological
45
46 conditions (AME2P, EA3533), 63000 Clermont-Ferrand, France

47
48
49
50
51 ***Correspondance to** Frédéric Dutheil, Occupational Medicine, University Hospital CHU G.
52
53 Montpied, 63000 Clermont-Ferrand, France Tel: +33 6 88 22 48 48. Fax: +33 4 73 27 46 49.
54
55 fred_dutheil@yahoo.fr.
56
57
58
59
60

1
2
3 Running Title: Capillaroscopy post-exposure to VCM
4

5 Words count for introduction methods results discussion conclusion: 2298
6

7 Number of tables: 1
8

9 Number of figures: 2
10

11 Words count for abstract: 258
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Objectives: To assess residual long-term microcirculation abnormalities by capillaroscopy, 15 years after retiring from occupational exposure to vinyl chloride monomer (VCM).

Design: Cross-sectional study.

Setting: Allier, one of the major area of PVC production in France.

Participants: We enrolled 761 male retired workers exposed to chemical toxics. Exposure to chemical other than VCM excluded potential participants.

Primary and secondary outcomes measures: These participants underwent a medical examination including a capillaroscopy, symptoms of Raynaud, and comorbidities, as well as a survey to determine exposure time, direct or indirect contact, type of occupation, smoking status and time after exposure. A double blind analysis of capillaroscopic images was done. A control group was matched in age, sex, type of occupation.

Results: 179/761 retired workers were only exposed to VCM at their work, with 21 meeting the inclusion criteria and included. Exposure time was 29.8 ± 1.9 years and time after exposure was 15.9 ± 2.4 years. Retired workers previously exposed to VCM had significantly higher capillaroscopic modifications than 35 controls: enlarged capillaries (19% vs. 0%, $p < .001$), dystrophy (28.6% vs. 0%, $p = .0012$), and augmented length (33% vs. 0%, $p < .001$). Time exposure was linked with enlarged capillaries (R^2 adjusted = 53%, $p < .0001$). They also had higher symptoms of Raynaud (19% vs. 0%, $p = .007$) without correlation with capillaroscopic modifications.

Conclusion: Although VCM exposure was already known to affect microcirculation, our study demonstrates residual long term abnormalities following an average of 15 years retirement, with a time-related exposure response. Symptoms of Raynaud, although statistically associated with exposure was not related to capillaroscopic modifications; its origin remains to be determined.

1
2
3 **Keywords** Exposition, Vinyl chloride monomer, Capillaroscopy, Raynaud
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ARTICLE SUMMARY**Article focus**

- Vinyl chloride monomer exposure induces microcirculation abnormalities, which can be diagnosed by capillaroscopy.
- Residual long-term abnormalities following retirement required investigation.

Key messages

- Our results demonstrated residual long-term abnormalities following an average of 15 years retirement, with a time-related exposure response.
- Symptoms of Raynaud, although statistically associated with exposure, was not related to capillaroscopic modifications; its origin remains to be determined.

Strengths and limitations of this study

- The strong points is that this study had a rigorous selection criteria of exclusively VCM exposed participants avoided confounding factor and the focus on retired workers at least 15 years after the end of occupational VCM exposure.
- The main limitation is that pathophysiology of Raynaud after VCM exposure remains unclear.

INTRODUCTION

Vinyl chloride monomer (VCM) is primarily used in the manufacture of plastics and also serves as a raw material in organic synthesis. VCM is an aliphatic hydrocarbon also known as chloroethene. Its polymerization lead to a synthetic resin called polyvinyl chloride, commonly abbreviated PVC. PVC, is the third-most widely produced plastic, after polyethylene and polypropylene.¹ PVC can be made softer and more flexible by the addition of phthalates, and may also replace rubber. Thus, PVC is widely used including: pipes and water distribution, a substitute for painted wood (e.g. window frames, sills, flooring), electrical cable insulation, inflatable products, waterproof clothing (e.g. coats, skiing equipment, shoes), healthcare products (e.g. containers, tubing, catheters), food packaging, dental appliances and vinyl records.¹

Harmless in its polymeric form, workers handling the finished PVC product are perfectly safe. In contrast, the at-risk phase lies in the manual descaling of autoclaves used for the polymerization where workers can contact it during its monomer state.² The chronic intoxication by gaseous monomer VCM is linked to several symptoms such as:³ asthenia and dizziness,³ Raynaud's syndrome,^{4 5} digestive ulcers with nausea and anorexia,³ systemic symptoms of arthralgia and myalgia³, trophic cutaneous symptoms and sclerosis. It has also been suspected in the onset of acroosteolysis^{4 6 7} and hepatocellular carcinoma.^{8 9} More generally, VCM exposure involves chromosomal aberrations and increased carcinogenic risk.¹⁰ Even if VCM related diseases may have a genetic bases, they are also linked to prolonged occupational VCM exposure.^{5 11}

Scleroderma-like microvascular abnormalities have been also described on exposed workers.¹²⁻¹⁴ The most common and non-invasive means of investigating these abnormalities is capillaroscopy. Widespread identification of individuals most at risk could enable early detection and treatment. The residual effects of VCM on microcirculation have been shown

1
2
3 only once on 15 workers who had ceased their VCM exposure six months prior to testing.¹³
4
5 However, residual long-term abnormalities following retirement are unknown. Our hypothesis
6
7 was higher capillaroscopic abnormalities in the VCM exposed group than in the control
8
9 group.
10
11 Therefore, the aim of our cross-sectional study was to investigate residual long-term
12
13 capillaroscopic abnormalities following retirement, after 15 years without VCM exposure.
14
15
16
17
18
19

20 21 **METHODS**

22 23 **Participants**

24
25 We enrolled male retired workers exposed to VCM in PVC production. They provided written
26
27 informed consent. The study was approved by the human ethics committees from Clermont-
28
29 Ferrand university hospital, France. To be eligible, participants had to be: male, retired, aged
30
31 over 60 years, with at least a 5-year occupational exposure to VCM, a time after VCM
32
33 exposure of at least 5 years, and no exposure to chemicals other than VCM. Moreover,
34
35 participants with diabetes mellitus were also excluded as it may interfere with
36
37 microcirculation,¹⁵⁻²⁰ as well as individuals declaring the use or previous use of treatments
38
39 which may alter microcirculation.
40
41
42

43 Participants responded to a survey to determine exposure time, direct or indirect contact, type
44
45 of occupation, time after exposure and smoking history. They underwent a medical
46
47 examination including a capillaroscopy, symptoms of Raynaud, and comorbidities such as
48
49 pathologies that may interfere with microcirculation (arterial hypertension, dyslipidemia) or
50
51 pathologies potentially linked with VCM exposure (cardiovascular or respiratory diseases).²¹
52
53
54
55
56
57
58
59
60

1
2
3 A control group was matched in age, sex, type of occupation. They were recruited via
4 advertisements. Selection criteria for this group also included no occupational or leisure
5 chemical exposure, and no diabetes mellitus.¹⁵⁻²⁰
6
7
8
9

10 11 12 **Capillaroscopy**

13 A nailfold capillaroscopy was performed on all fingers of each patient, excluding thumbs.²²

14 The nailfold capillaroscopies of the fingers were captured in images and electronically stored.

15 The same investigator conducted all the capillaroscopies. A double blind analysis of
16 capillaroscopic images was completed on deidentified data.
17
18

19 The outcomes were the five following classical criteria used in capillaroscopy:²³ density,
20 length, diameter, dystrophy and hemorrhage. Criteria for abnormalities were defined as:
21 decreased capillary density <10/mm (avascular zone <7/mm), augmented capillary length
22 >300µm, increased capillary diameter >30µm (megacapillary >50µm), and dystrophy was
23 associated with capillary branching >15%.
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Statistics**

38 Data are presented as mean percentage change and standard deviation (SD).

39 The main judgment criterion for abnormal microcirculation was the presence of at least one
40 abnormality in capillaroscopy. The most common abnormality is capillary dystrophy.²³

41 Previous data^{2 23} and personal observation on residual long-term abnormalities following
42 VCM exposure showed that a percentage of dystrophy of approximately 25% was required to
43 differentiate between the exposed group and the controls. Using this value as the main
44 outcome, we calculated that a sample of 10 participants per group allows a statistical power
45 greater than 80% with an alpha level less than 5%.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Statistical analyses were performed with SPSS software, v19. The Gaussian distribution for
4 each parameter was assessed by a Shapiro-Wilk test. Comparisons between groups (exposed
5 vs. control) were made through the usual tests: Chi2 test for categorical variables (or Fisher's
6 exact test where appropriate) and Student's t test for quantitative variables (or Kruskal-Wallis
7 if assumptions of normal distribution were violated). Significance was accepted for a p-value
8 < 5%. A matrix of the correlations between the outcomes and exposure was determined using
9 a non parametric Spearman test. Multivariate models were used to predict the relationship
10 between capillary parameters and other parameters such as exposure time and time after
11 exposure.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **RESULTS**

31 **Participants**

32 We enrolled 761 male retired workers exposed to chemical toxics from two leading enterprises
33 involved in PVC production (n=435 and n=91), as well as participants from many
34 subcontracting companies (n=235), also known for VCM exposure. The strict selection
35 criteria of exposure only to VCM reduced the sample size to 21 (figure 1).
36
37
38
39
40
41

42 Thirty five age-matched controls were also recruited without occupational or leisure time
43 exposure to chemical toxics.
44
45
46
47
48

49 **Main capillaroscopic outcomes**

50 There was no missing data. Double blinded analysis showed no statistical difference between
51 the two investigators.
52
53
54
55
56
57
58
59
60

1
2
3 Compared with controls, retired workers previously exposed to VCM had higher
4 capillaroscopic abnormalities: enlarged capillaries (0% vs. 19%, $p<.001$), dystrophy (0% vs.
5 28.6%, $p=.0012$) (figure 2), and augmented length (0% vs. 33%, $p<.001$). The mean length
6 was higher in the exposed group than in controls ($291\pm 14\mu$ vs. $254\pm 9\mu$, $p=.020$), as well as
7 the mean diameter of capillaries ($28.9\pm 0.9\mu$ vs. $25.7\pm 0.6\mu$, $p=.006$) (table 1).
8
9
10
11
12

13 14 15 16 **Exposure**

17 Exposure time was 29.8 ± 1.9 years and time after exposure was 15.9 ± 2.4 years. Time of
18 exposure to VCM was strongly linked with enlarged capillaries (R^2 adjusted = 53%, $p<.0001$)
19 and modestly linked with capillary length (R^2 adjusted = 8%; $p=.031$) (table 1). Age was not
20 associated with capillaroscopic abnormalities.
21
22
23
24
25
26
27

28 29 30 **Symptoms of Raynaud**

31 VCM exposed group also had more symptoms of Raynaud (19% vs. 0%, $p=.007$) independent
32 of capillaroscopic modifications (table 1).
33
34
35
36
37
38
39

40 41 42 **Comorbidities and smoking**

43 Neither respiratory nor cardiovascular diseases were associated with VCM exposure.
44 However, we combined both groups to explore potential associations between capillaroscopic
45 parameters and high blood pressure, dyslipidemia, and smoking. Capillary length in
46 participants medicated for arterial hypertension ($n=20/61$) did not differ from participants
47 without hypertension. Participants treated with lipid lowering drugs with dyslipidemia
48 ($n=10/61$) also showed a trend for a higher capillary length than participants without
49 dyslipidemia ($p=.079$). Finally, there were no capillaroscopic difference between smokers and
50
51
52
53
54
55
56
57
58
59
60

1
2
3 non smokers. However, smokers who had been exposed to VCM tended to have a higher
4
5 capillary length than non smokers (p=.073).
6
7
8
9

10 11 12 **DISCUSSION**

13 14 15 16 17 **Principal findings of the study**

18
19 Changes in microcirculation persist for at least 15 years following occupational VCM
20
21 exposure, with a time-related exposure response. Symptoms of Raynaud, although statistically
22
23 associated with exposure, was not related to pathological capillaroscopic changes.
24
25

26 27 28 **what the study adds**

29
30 The microcirculation changes following VCM exposure has been previously shown on 15
31
32 workers who ceased their occupational exposure six months prior to testing.¹³ Our study
33
34 supports these results over a longer period following VCM exposure – 15 years.
35

36
37 The dose responsiveness of VCM exposure and compromised capillarisation is well
38
39 accepted.¹³ Although daily VCM doses may have been more informative, the current study
40
41 was restricted to years of exposure. Thus, we are limited to describing associations with an
42
43 exposure time – response rather than a dose-response.
44

45
46 The absence of changes in microcirculation on less exposed workers²⁴ resulted in a suggestion
47
48 that a threshold of exposure exists. This finding is supported by previous studies showing that
49
50 long-term exposure (>8 years) induced greater chromosomal aberrations.^{10 25} Further, not all
51
52 workers exposed to VCM develop microvascular abnormalities, suggestive of an underlying
53
54 genetic susceptibility (polymorphism of glutathione S-transferase).^{5 11} A finding that female
55
56
57
58
59
60

1
2
3 VCM-exposed workers were more susceptible than males to the risk of increased
4
5 chromosome damage also reinforced genetic susceptibility theory.²⁵
6
7
8

9 10 **Comparison with other studies**

11 After 50 years, minor dystrophies could alter readability and interpretation of capillaroscopic
12 analyses.²⁶ Nevertheless, we controlled this parameter by matching the exposed group and the
13 controls on age and we conducted a double-blind analysis by two experienced readers.
14
15 Moreover, capillaroscopic abnormalities among workers exposed to VCM in the present study
16 were not influenced by age.¹³
17
18

19 VCM has been suspected of causing respiratory and circulatory diseases.²⁷ However, similar
20 frequencies of these diseases in both groups do not support this hypothesis.
21
22

23 Diabetes mellitus,¹⁵⁻²⁰ high blood pressure,^{17 28-30} dyslipidemia,²⁹ or some
24 comorbidities/medications²¹ could interfere with microcirculation. In line with previous
25 studies, we showed a diminished capillary length in participants treated for arterial
26 hypertension,^{17 28-30} and a trend for participants treated with lipid lowering drugs.²⁹ Diabetes
27 mellitus was an exclusion criterion and thus, could not interfere with our results. Perhaps due
28 to low numbers of participants, our results failed to support previous findings of compromised
29 microcirculation in people with high blood pressure. The trend for increased capillary length
30 observed in our participants with dyslipidemia could be a response to increased peripheral
31 vascular resistance, in order to maintain their function of metabolic exchange.³⁰ Similarly,
32 smoking could induce a decrease in tissue perfusion,³¹ and dystrophia.³² We did not observe
33 differences between smokers and non-smokers, with the exception of a trend for abnormal
34 microcirculation among smokers exposed to VCM. The potential of a synergistic effect of
35 tobacco and VCM-exposure warrants further investigations. It should be noted that VCM
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 exposure in the current study was more strongly associated with compromised
4 microcirculation than high blood pressure, dyslipidemia and smoking.
5
6

7 A higher prevalence of symptoms of Raynaud has been established in workers with VCM
8 exposure,²⁷ up to one third of the exposed workers.¹³ Our results support these data, and
9 extend knowledge by demonstrating the prevalence of symptoms of Raynaud remained higher
10 at least 15 years following VCM exposure. Furthermore, in the current study, all the
11 participants who suffered from symptoms of Raynaud had never taken medications or
12 suffered from other diseases conducive to Raynaud.
13
14
15
16
17
18
19
20
21
22

23 **Unanswered questions**

24 Although symptoms of Raynaud are statistically associated with VCM exposure, we could not
25 report a link with capillaroscopic modifications. The pathophysiology of Raynaud's
26 phenomenon remains unknown. There seems to be primary or secondary vascular failure
27 influenced by a hereditary factor.³³ Decreased perfusion pressure could be secondary to
28 systemic hypotension or be caused by proximal arterial occlusion, influenced by many
29 factors; both vascular and intra vascular, neural, environmental or hereditary.³⁴ Angiography
30 of the hands of patients exposed to VCM showed occlusions, stenosis and narrowing of distal
31 arteries with the development of collateral circulation.³⁵ Lack of statistical power in our study
32 could contribute to the lack of relationship between capillaroscopic changes and symptoms of
33 Raynaud.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Strengths and limitations of study**

51 This study presents some major strengths: a rigorous selection criteria of exclusively VCM
52 exposed participants avoided confounding factors, well-matched controls, a double blind
53 analyses, sufficient number of participants to detect the capillaroscopic differences between
54
55
56
57
58
59
60

1
2
3 groups, the focus on retired workers at least 15 years after the end of occupational VCM
4 exposure. The attendance rate of 30% (53 of 179 individuals exclusively exposed to VCM at
5 work agreed to participate in our study) seems very high compared with other studies³⁶⁻⁴⁰
6
7 taking into account their age (75 years), distance from the location of the medical examination
8
9 (averaging approximately 80 km), and that no financial compensation was offered.
10
11

12
13
14 There are limitations to this study: a cross-sectional design however, proof of concept was
15 important and achieved (with a possibility of longitudinal follow-up); differences in some but
16 not all capillary outcomes may be explained by a lack of power; the results are insufficient to
17 propose guidelines for all workers exposed to VCM; more accurate quantifiable measures of
18 VCM exposure are not available, however for the purpose of this study we used industry
19 established lists of exposure legally required in France; we combined our knowledge only use a
20 binary pathophysiology of Raynaud after VCM exposure remains unclear, most of the retired
21 workers exposed to VCM were from the same enterprise; and potentially more at-risk
22 manufacturing processes remained undetected.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 CONCLUSION

41
42 Although VCM exposure was already known to affect microcirculation, our study
43 demonstrated residual long-term abnormalities following an average of 15 years retirement,
44 with a time exposure – response. Symptoms of Raynaud, although statistically associated with
45 exposure were not associated with capillaroscopic modifications; its origin remains to be
46 determined. Future research could focus on other chemical products which have a similar
47 structure than VCM and more extensive research on type of occupations at-risk of VCM
48 exposure.
49
50
51
52
53
54
55
56
57
58
59
60

Role of the Funding Source

The Occupational Medicine department of CHU G. Montpied, Clermont-Ferrand, France funded this study. No other funding source had a role in the design, conduct, or reporting of the study.

Contributors

VL has participated as a MD student and principal investigator. FD and AC obtained research funding and generated the intellectual development of the study. FD knew potential exposed workers to VCM. VL, FD, AC and SH contributed to the conception of the protocol. VL, FD and SH made data analysis. VL, FD, MT contributed to manuscript drafting. VL recruited all participants and performed all capillaroscopies. VL and MT completed the double blind analyses of capillaroscopy. FD, AC, VL, GN and MT revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

Our thanks to Geraldine Naughton for help with manuscript English proof reading. We also want to acknowledge the “Association of the sick from chemicals” (Association des Malades de la Chimie), 15 Av Albert Poncet 03410 Domerat, France, which helped us recruit the retired workers from VCM exposure.

REFERENCES

- 1 Allsopp M, Giovanni G. Poly(Vinyl Chloride) *Ullmann's Encyclopedia of Industrial Chemistry* 2000.
- 2 Fontana L, Baietto M, Becker F, Catilina P. [Clinical and capillaroscopic study of Raynaud's phenomenon in retired patients previously exposed to vinyl chloride monomer]. *J Mal Vasc* 1995;20:268-73.


- 1
2
3 Veltman G, Lange CE, Juhe S, Stein G, Bachner U. Clinical manifestations and course
4 of vinyl chloride disease. *Ann NY Acad Sci* 1975;246:6-17.
- 5 Harris DK, Adams WG. Acro-osteolysis occurring in men engaged in the
6 polymerization of vinyl chloride. *Br Med J* 1967;3:712-4.
- 7 Fontana L, Marion MJ, Ughetto S, Catilina P. Glutathione S-transferase M1 and GST
8 T1 genetic polymorphisms and Raynaud's phenomenon in French vinyl chloride
9 monomer-exposed workers. *J Hum Genet* 2006;51:879-86.
- 10 Preston BJ, Jones KL, Grainger RG. Clinical aspects of vinyl chloride disease: acro-
11 osteolysis. *Proc R Soc Med* 1976;69:284-6.
- 12 Wilson RH, McCormick WE, Tatum CF, Creech JL. Occupational acroosteolysis.
13 Report of 31 cases. *JAMA* 1967;201:577-81.
- 14 Dragani TA, Zocchetti C. Occupational exposure to vinyl chloride and risk of
15 hepatocellular carcinoma. *Cancer Causes Control* 2008;19:1193-200.
- 16 Mundt KA, Dell LD, Austin RP, Luippold RS, Noess R, Bigelow C. Historical cohort
17 study of 10 109 men in the North American vinyl chloride industry, 1942-72: update
18 of cancer mortality to 31 December 1995. *Occup Environ Med* 2000;57:774-81.
- 19 Kumar AK, Balachandar V, Arun M et al. A Comprehensive Analysis of Plausible
20 Genotoxic Covariates Among Workers of a Polyvinyl Chloride Plant Exposed to
21 Vinyl Chloride Monomer. *Arch Environ Contam Toxicol* 2012.
- 22 Ji F, Zhu S, Sun P, Wang W. [Relationship between genetic polymorphisms of phase I
23 and phase II metabolizing enzymes and DNA damage of workers exposed to vinyl
24 chloride monomer]. *Wei Sheng Yan Jiu* 2009;38:7-11.
- 25 Langauer-Lewowicka H. Nailfolds capillary abnormalities in polyvinyl chloride
26 production workers. *Int Arch Occup Environ Health* 1983;51:337-40.
- 27 Maricq HR, Darke CS, Archibald RM, Leroy EC. In vivo observations of skin
28 capillaries in workers exposed to vinyl chloride. An English-American comparison. *Br
29 J Ind Med* 1978;35:1-7.
- 30 Maricq HR, Johnson MN, Whetstone CL, LeRoy EC. Capillary abnormalities in
31 polyvinyl chloride production workers. Examination by in vivo microscopy. *JAMA*
32 1976;236:1368-71.
- 33 Pazos-Moura CC, Moura EG, Bouskela E, Torres Filho IP, Breitenbach MM. Nailfold
34 capillaroscopy in non-insulin dependent diabetes mellitus: blood flow velocity during
35 rest and post-occlusive reactive hyperaemia. *Clin Physiol* 1990;10:451-61.
- 36 Iabichella ML, Mariotti R, Nuti M, Balbarini A, Mariani M. [Site specificity of
37 biomicroscopic pattern in diabetic patients]. *Minerva Cardioangiol* 1999;47:619-21.
- 38 Lambova SN, Muller-Ladner U. The specificity of capillaroscopic pattern in
39 connective autoimmune diseases. A comparison with microvascular changes in
40 diseases of social importance: arterial hypertension and diabetes mellitus. *Mod
41 Rheumatol* 2009;19:600-5.
- 42 Vayssairat M, Le Devehat C. [Critical analysis of vascular explorations in diabetic
43 complications]. *J Mal Vasc* 2001;26:122-5.
- 44 Meyer MF, Pfohl M, Schatz H. [Assessment of diabetic alterations of microcirculation
45 by means of capillaroscopy and laser-Doppler anemometry]. *Med Klin (Munich)*
46 2001;96:71-7.
- 47 Chang CH, Tsai RK, Wu WC, Kuo SL, Yu HS. Use of dynamic capillaroscopy for
48 studying cutaneous microcirculation in patients with diabetes mellitus. *Microvasc Res*
49 1997;53:121-7.
- 50 Gallucci F, Russo R, Buono R, Acampora R, Madrid E, Uomo G. Indications and
51 results of videocapillaroscopy in clinical practice. *Adv Med Sci* 2008;53:149-57.
- 52
53
54
55
56
57
58
59
60

- 1
2
3 22 Hern S, Mortimer PS. Visualization of dermal blood vessels--capillaroscopy. *Clin Exp Dermatol* 1999;24:473-8.
- 4
5 23 Kabasakal Y, Elvins DM, Ring EF, McHugh NJ. Quantitative nailfold capillaroscopy
6 findings in a population with connective tissue disease and in normal healthy controls.
7 *Ann Rheum Dis* 1996;55:507-12.
- 8
9 24 Przybylowski J, Podolecki A, Laks L et al. [Health status of workers in polyvinyl
10 chloride processing plants. I. Evaluation of occupational exposure. Subjective and
11 capillaroscopy studies. Conduction velocity in the motor nerves]. *Med Pr*
12 1983;34:385-96.
- 13
14 25 Jiao J, Feng NN, Li Y et al. Estimation of a Safe Level for Occupational Exposure to
15 Vinyl Chloride Using a Benchmark Dose Method in Central China. *J Occup Health*
16 2012.
- 17
18 26 Carpentier PH. New techniques for clinical assessment of the peripheral
19 microcirculation. *Drugs* 1999;59 Spec No:17-22.
- 20
21 27 Laplanche A, Clavel F, Contassot JC, Lanouziere C. Exposure to vinyl chloride
22 monomer: report on a cohort study. *Br J Ind Med* 1987;44:711-5.
- 23
24 28 Prasad A, Dunnill GS, Mortimer PS, MacGregor GA. Capillary rarefaction in the
25 forearm skin in essential hypertension. *J Hypertens* 1995;13:265-8.
- 26
27 29 Bonacci E, Santacroce N, D'Amico N, Mattace R. Nail-fold capillaroscopy in the
28 study of microcirculation in elderly hypertensive patients. *Arch Gerontol Geriatr*
29 1996;22 Suppl 1:79-83.
- 30
31 30 Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Structural
32 skin capillary rarefaction in essential hypertension. *Hypertension* 1999;33:998-1001.
- 33
34 31 Lehr HA. Microcirculatory dysfunction induced by cigarette smoking.
35 *Microcirculation* 2000;7:367-84.
- 36
37 32 Lova RM, Miniati B, Macchi C et al. Morphologic changes in the microcirculation
38 induced by chronic smoking habit: a videocapillaroscopic study on the human labial
39 mucosa. *Am Heart J* 2002;143:658.
- 40
41 33 Block JA, Sequeira W. Raynaud's phenomenon. *Lancet* 2001;357:2042-8.
- 42
43 34 Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. *Nat*
44 *Rev Rheumatol* 2012;8:469-79.
- 45
46 35 Koischwitz D, Marsteller HJ, Lackner K, Brecht G, Brecht T. [Changes in the arteries
47 in the hand and fingers due to vinyl chloride exposure (author's transl)]. *Rofo*
48 1980;132:62-8.
- 49
50 36 Dutheil F, Kelly C, Biat I et al. [Relation between the level of knowledge and the rate
51 of vaccination against the flu virus among the staff of the Clermont-Ferrand
52 University hospital]. *Med Mal Infect* 2008;38:586-94.
- 53
54 37 Chiew M, Weber MF, Egger S, Sitas F. A cross-sectional exploration of smoking
55 status and social interaction in a large population-based Australian cohort. *Social*
56 *Science and Medicine* 2012;75:77-86.
- 57
58 38 Penformis A, San-Galli F, Cimino L, Huet D. Current insulin therapy in patients with
59 type 2 diabetes: results of the ADHOC survey in France. *Diabetes and Metabolism*
60 2011;37:440-5.
- 61
62 39 Heinavaara S, Tokola K, Kurttio P, Auvinen A. Validation of exposure assessment
63 and assessment of recruitment methods for a prospective cohort study of mobile phone
64 users (COSMOS) in Finland: a pilot study. *Environ Health* 2011;10:14.
- 65
66 40 Eriksen L, Gronbaek M, Helge JW, Tolstrup JS, Curtis T. The Danish Health
67 Examination Survey 2007-2008 (DANHES 2007-2008). *Scand J Public Health*
68 2011;39:203-11.


Table 1 Characteristics of participants, exposure to VCM and capillaroscopic outcomes.

	Retired from exposure to VCM (n=21)	Controls (n=40)	p- value
Age – years	74.4±2.9	76.3±3.2	NS
type of occupation: blue collar workers – “manual”	100%	100%	NS
Exposure to VCM:			
direct contact with VCM	100%	0	<.001
exposure time – years	29.8±1.9	0	<.001
time after exposure – years	15.9±2.4	-	-
Main capillaroscopic outcomes:			
1. density			
mean density – mm	8.6±0.4	8.8±0.3	NS
decreased capillary density <10/mm – n (%)	9 (43)	16 (46)	NS
avascular zone <7/mm – n(%)	0	0	NS
2. length			
mean length – mm	291±14µ	254±9µ	.020
augmented capillary length >300µm – n(%)	7 (33)	0	<.001
3. diameter			
mean diameter of capillaries – mm	28.9±0.9µ	25.7±0.6µ	.006
enlarged capillaries >30µm – n(%)	4 (19)	0	<.001
megacapillary >50µm – n(%)	0	0	NS
4. dystrophy			
capillary branching >15% – n(%)	6 (29)	0	<.001
5. hemorrhage – n(%)			
	0	0	NS
Symptoms of Raynaud:			
n(%) with Raynaud	4 (19)	0	.007
Participants with medications which could induce Raynaud – n(%)	2 (9)	4 (11)	NS
Other causes of Raynaud	0	0	NS
Comorbidities			
Respiratory diseases	2 (9)	6 (17)	NS
Cardiovascular diseases (except high blood pressure)	4 (19)	5 (14)	NS
Myocardial infraction	3 (14)	3(9)	NS
Routine medications – n(%) of patients treated for:			
Blood pressure	7 (33)	13 (37)	NS
Lipid lowering	4 (19)	6 (17)	NS
Smoking – n(%)	9 (43)	18 (51)	NS

Figure 1 Participant flow chart.



1
2
3 **Figure 2** Normal capillaroscopy on a control participant (A) and capillaroscopy with
4 dystrophia >15% in a retired worker exposed to VCM for 37 years, with no treatment and no
5 comorbidity, non smoking (B).
6
7
8



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cross-sectional studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	19 (figure 1)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	8-9
		(c) Explain how missing data were addressed	8-9
		(d) If applicable, describe analytical methods taking account of sampling strategy	8-9
		(e) Describe any sensitivity analyses	8-9
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	19 (figure 1)
		(b) Give reasons for non-participation at each stage	19 (figure 1)
		(c) Consider use of a flow diagram	19 (figure 1)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7;9; 19 (figure 1)
		(b) Indicate number of participants with missing data for each variable of interest	9
Outcome data	15*	Report numbers of outcome events or summary measures	9-10; 19 (figure 1)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10; 19 (figure 1)
		(b) Report category boundaries when continuous variables were categorized	9-10; 19 (figure 1)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-10
Discussion			
Key results	18	Summarise key results with reference to study objectives	11-13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



The long-term effects of occupational exposure to vinyl chloride monomer on microcirculation: a cross-sectional study 15 years after retirement

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002785.R1
Article Type:	Research
Date Submitted by the Author:	04-Apr-2013
Complete List of Authors:	Lopez, Vincent; CHU G. Montpied, Chamoux, Alain; CHU G. Montpied, Tempier, Marion; CHU G. Montpied, Thiel, Helene; CHU G. Montpied, Ughetto, Sylvie; CHU G. Montpied, Trousselard, Marion; IRBA, Naughton, Geraldine; Australian Catholic University, School of Exercise Science Dutheil, Frederic; CHU G. Montpied,
Primary Subject Heading:	Occupational and environmental medicine
Secondary Subject Heading:	Public health
Keywords:	OCCUPATIONAL & INDUSTRIAL MEDICINE, CHEMICAL PATHOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	19 (figure 1)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	8-9
		(c) Explain how missing data were addressed	8-9
		(d) If applicable, describe analytical methods taking account of sampling strategy	8-9
		(e) Describe any sensitivity analyses	8-9
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	19 (figure 1)
		(b) Give reasons for non-participation at each stage	19 (figure 1)
		(c) Consider use of a flow diagram	19 (figure 1)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7;9; 19 (figure 1)
		(b) Indicate number of participants with missing data for each variable of interest	9
Outcome data	15*	Report numbers of outcome events or summary measures	9-10; 19 (figure 1)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10; 19 (figure 1)
		(b) Report category boundaries when continuous variables were categorized	9-10; 19 (figure 1)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-10
Discussion			
Key results	18	Summarise key results with reference to study objectives	11-13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

1
2
3 **The long-term effects of occupational exposure to vinyl chloride monomer**
4
5 **on microcirculation: a cross-sectional study 15 years after retirement**
6
7
8
9

10
11
12
13 Vincent Lopez ¹, Alain Chamoux ¹, Marion Tempier ², H el ene Thiel ³, Sylvie Ughetto ⁴,
14
15 Marion Trousselard ⁵, Geraldine Naughton ⁶, Fr ed eric Dutheil ^{1,6,7,*}
16
17

18
19
20 ¹ Occupational Medicine, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand,
21
22 France

23
24 ² Radiopharmacy, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand, France

25
26 ³ Vascular Medicine, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand,
27
28 France

29
30
31 ⁴ Department of Medical Information - Clinical research and innovation direction, University
32
33 Hospital CHU G. Montpied, 63000 Clermont-Ferrand, France

34
35 ⁵ Neurophysiology of emotions, ENOP department, CRSSA/IRBA, 38702 La Tronche,
36
37 France

38
39
40 ⁶ School of Exercise Science, Australian Catholic University, Locked Bag 4115 Fitzroy MDC
41
42 VIC 3065, Australia

43
44 ⁷ Laboratory of Metabolic Adaptations to Exercise in Physiological and Pathological
45
46 conditions (AME2P, EA3533), 63000 Clermont-Ferrand, France

47
48
49
50
51 ***Correspondance to** Fr ed eric Dutheil, Occupational Medicine, University Hospital CHU G.
52
53 Montpied, 63000 Clermont-Ferrand, France Tel: +33 6 88 22 48 48. Fax: +33 4 73 27 46 49.
54
55 fred_dutheil@yahoo.fr.
56
57
58
59
60

1
2
3 Running Title: Capillaroscopy post-exposure to VCM
4

5 Words count for introduction methods results discussion conclusion: 2298
6

7 Number of tables: 1
8

9 Number of figures: 2
10

11 Words count for abstract: 258
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Objectives: To assess residual long-term microcirculation abnormalities by capillaroscopy, 15 years after retiring from occupational exposure to vinyl chloride monomer (VCM).

Design: Cross-sectional study.

Setting: Allier, one of the major area of PVC production in France.

Participants: We screened 761 (97% males) retired workers exposed to chemical toxics. Exposure to chemical other than VCM excluded potential participants.

Primary and secondary outcomes measures: These participants underwent a medical examination including a capillaroscopy, symptoms of Raynaud, and comorbidities, as well as a survey to determine exposure time, direct or indirect contact, type of occupation, smoking status and time after exposure. A double blind analysis of capillaroscopic images was done. A control group was matched in age, sex, type of occupation.

Results: 179/761 retired workers were only exposed to VCM at their work, with 21 meeting the inclusion criteria and included. Exposure time was 29.8 ± 1.9 years and time after exposure was 15.9 ± 2.4 years. Retired workers previously exposed to VCM had significantly higher capillaroscopic modifications than 35 controls: enlarged capillaries (19% vs. 0%, $p < .001$), dystrophy (28.6% vs. 0%, $p = .0012$), and augmented length (33% vs. 0%, $p < .001$). Time exposure was linked with enlarged capillaries (R^2 adjusted = 63%, $p < .0001$). They also had higher symptoms of Raynaud (19% vs. 0%, $p = .007$) without correlation with capillaroscopic modifications.

Conclusion: Although VCM exposure was already known to affect microcirculation, our study demonstrates residual long term abnormalities following an average of 15 years retirement, with a time-related exposure response. Symptoms of Raynaud, although statistically associated with exposure was not related to capillaroscopic modifications; its origin remains to be determined.

1
2
3 **Keywords** Exposition, Vinyl chloride monomer, Capillaroscopy, Raynaud
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ARTICLE SUMMARY**Article focus**

- Vinyl chloride monomer exposure induces microcirculation abnormalities, which can be diagnosed by capillaroscopy.
- Residual long-term abnormalities following retirement required investigation.

Key messages

- Our results demonstrated residual long-term abnormalities following an average of 15 years retirement, with a time-related exposure response.
- Symptoms of Raynaud, although statistically associated with exposure, was not related to capillaroscopic modifications; its origin remains to be determined.

Strengths and limitations of this study

- The strong points is that this study had a rigorous selection criteria of exclusively VCM exposed participants avoided confounding factor and the focus on retired workers at least 15 years after the end of occupational VCM exposure.
- The main limitation is that pathophysiology of Raynaud after VCM exposure remains unclear.

INTRODUCTION

Vinyl chloride monomer (VCM) is primarily used in the manufacture of plastics and also serves as a raw material in organic synthesis. VCM is an aliphatic hydrocarbon also known as chloroethene. Its polymerization lead to a synthetic resin called polyvinyl chloride, commonly abbreviated PVC. PVC, is the third-most widely produced plastic, after polyethylene and polypropylene.¹ PVC can be made softer and more flexible by the addition of phthalates, and may also replace rubber. Thus, PVC is widely used including: pipes and water distribution, a substitute for painted wood (e.g. window frames, sills, flooring), electrical cable insulation, inflatable products, waterproof clothing (e.g. coats, skiing equipment, shoes), healthcare products (e.g. containers, tubing, catheters), food packaging, dental appliances and vinyl records.¹

Harmless in its polymeric form, workers handling the finished PVC product are perfectly safe. In contrast, the at-risk phase lies in the manual descaling of autoclaves used for the polymerization where workers can contact it during its monomer state.² The chronic intoxication by gaseous monomer VCM is linked to several symptoms such as:³ asthenia and dizziness,³ Raynaud's syndrome,^{4 5} digestive ulcers with nausea and anorexia,³ systemic symptoms of arthralgia and myalgia³, trophic cutaneous symptoms and sclerosis. It has also been suspected in the onset of acroosteolysis^{4 6 7} and hepatocellular carcinoma.^{8 9} More generally, VCM exposure involves chromosomal aberrations and increased carcinogenic risk.¹⁰ Even if VCM related diseases may have a genetic bases, they are also linked to prolonged occupational VCM exposure.^{5 11}

Scleroderma-like microvascular abnormalities have been also described on exposed workers.¹²⁻¹⁴ The most common and non-invasive means of investigating these abnormalities is capillaroscopy. Widespread identification of individuals most at risk could enable early detection and management strategy.¹⁵ The residual effects of VCM on microcirculation have

1
2
3 been shown only once on 15 workers who had ceased their VCM exposure six months prior to
4 testing.¹³ However, residual long-term abnormalities following retirement are unknown. Our
5
6 hypothesis was higher capillaroscopic abnormalities in the VCM exposed group than in the
7
8 control group.
9

10
11 Therefore, the aim of our cross-sectional study was to investigate residual long-term
12
13 capillaroscopic abnormalities following retirement, after 15 years without VCM exposure.
14
15

16 17 18 19 20 21 **METHODS**

22 23 **Participants**

24
25 We enrolled male retired workers exposed to VCM in PVC production. They provided written
26
27 informed consent. The study was approved by the human ethics committees from Clermont-
28
29 Ferrand university hospital, France. To be eligible, participants had to be: male (due to male
30
31 dominance in this workforce), retired, aged over 60 years, with at least a 5-year occupational
32
33 exposure to VCM, a time after VCM exposure of at least 5 years, and no exposure to
34
35 chemicals other than VCM. Moreover, participants with diabetes mellitus were also excluded
36
37 as it may interfere with microcirculation,¹⁶⁻²¹ as well as individuals declaring the use or
38
39 previous use of treatments which may alter microcirculation.
40
41

42
43 Participants responded to a survey to determine exposure time, direct or indirect contact, type
44
45 of occupation, time after exposure and smoking history. They underwent a medical
46
47 examination including a capillaroscopy, symptoms of Raynaud, and comorbidities such as
48
49 pathologies that may interfere with microcirculation (arterial hypertension, dyslipidemia) or
50
51 pathologies potentially linked with VCM exposure (cardiovascular or respiratory diseases).²²
52
53
54
55
56
57
58
59
60

1
2
3 A control group was matched in age, sex, type of occupation. They were recruited via
4 advertisements. Selection criteria for this group also included no occupational or leisure
5 chemical exposure, and no diabetes mellitus.¹⁶⁻²¹
6
7
8
9

10 11 12 **Capillaroscopy**

13 A nailfold capillaroscopy was performed on all fingers of each patient, excluding thumbs.²³
14 The nailfold capillaroscopies of the fingers were captured in images and electronically stored.
15 The same investigator conducted all the capillaroscopies. A double blind analysis of
16 capillaroscopic images was completed on deidentified data.
17
18
19
20
21
22

23 The outcomes were the five following classical criteria used in capillaroscopy: density,
24 length, diameter, dystrophy and hemorrhage. Criteria for abnormalities were defined as:
25 decreased capillary density $<10/\text{mm}$ (avascular zone $<7/\text{mm}$),²⁴ augmented capillary length
26 $>300\mu\text{m}$,^{24 25} increased capillary diameter $>25\mu\text{m}$ ²⁵ (megacapillary $>50\mu\text{m}$)^{26 27}, and
27 dystrophy was associated with capillary branching $>15\%$.²⁸ Hemorrhage is defined as the
28 microvascular extravasation of the red blood cells linked to the damage of the vessel wall.²⁷
29
30
31
32
33
34
35
36
37
38

39 **Statistics**

40 Data are presented as mean percentage change and standard deviation (SD).

41 The main judgment criterion for abnormal microcirculation was the presence of at least one
42 abnormality in capillaroscopy. The most common abnormality is capillary dystrophy.²⁵
43 Previous data^{2 25} and personal observation on residual long-term abnormalities following
44 VCM exposure showed that a percentage of dystrophy of approximately 25% was required to
45 differentiate between the exposed group and the controls. Using this value as the main
46 outcome, we calculated that a sample of 10 participants per group allows a statistical power
47 greater than 80% with an alpha level less than 5%.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Statistical analyses were performed with SPSS software, v19. Correlations were used for
4 inter-observer reliability. The Gaussian distribution for each parameter was assessed by a
5 Shapiro-Wilk test. Comparisons between groups (exposed vs. control) were made through the
6 usual tests: Chi2 test for categorical variables (or Fisher's exact test where appropriate) and
7 Student's t test for quantitative variables (or Kruskal-Wallis if assumptions of normal
8 distribution were violated). Significance was accepted for a p-value < 5%. The links between
9 continuous variables were analyzed using linear regression. The links between binary and
10 continuous variables were analyzed with logistic regression. Multivariate models were used to
11 predict the relationship between capillary parameters and other parameters such as exposure
12 time and time after exposure.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **RESULTS**

30 **Participants**

31
32
33
34 We screened 761 (97% males) retired workers exposed to chemical toxics from two leading
35 enterprises involved in PVC production (n=435 and n=91), as well as participants from many
36 subcontracting companies (n=235), also known for VCM exposure. The strict selection
37 criteria of exposure only to VCM reduced the sample size to 21 (figure 1).
38
39
40
41
42
43
44

45 Thirty five age-matched controls were also recruited without occupational or leisure time
46 exposure to chemical toxics.
47
48
49

50 **Main capillaroscopic outcomes**

51
52 There was no missing data. Inter-rater reliability was confirmed with correlations exceeding
53 0.70 for each parameter. The mean of the values of the 2 investigators is presented in table 1.
54
55
56
57
58
59
60

1
2
3 Concerning the qualitative data, when a disagreement occurred, the two observers analyzed
4 again together and requested the opinion of a third expert. The disagreement occurred only for
5
6
7 2 decreased capillary density <10/mm, and 1 capillary branching >15%.

8
9 Compared with controls, retired workers previously exposed to VCM had higher
10 capillaroscopic abnormalities: enlarged capillaries (0% vs. 19%, $p<.001$), dystrophy (0% vs.
11 28.6%, $p=.0012$) (figure 2), and augmented length (0% vs. 33%, $p<.001$). The mean length
12 was 15% higher in the exposed group than in controls ($p=.020$), as well as a 12% greater
13 diameter of capillaries ($p=.006$) (table 1).
14
15
16
17
18
19

20 21 22 23 **Exposure**

24 Exposure time was 29.8 ± 1.9 years and time after exposure was 15.9 ± 2.4 years. Time of
25 exposure to VCM was strongly linked with enlarged capillaries (R^2 adjusted = 63%, $p<.0001$)
26 and modestly linked with capillary length ($R^2 = 8\%$; $p=.031$) (table 1). Age was not associated
27 with capillaroscopic abnormalities. No multivariate models improved results from simple
28 regressions.
29
30
31
32
33
34
35
36
37
38

39 **Symptoms of Raynaud**

40 VCM exposed group also had more symptoms of Raynaud (19% vs. 0%, $p=.007$) independent
41 of capillaroscopic modifications (table 1).
42
43
44
45
46
47

48 **Comorbidities and smoking**

49 Neither respiratory nor cardiovascular diseases were associated with VCM exposure.
50 However, we combined both groups to explore potential associations between capillaroscopic
51 parameters and high blood pressure, dyslipidemia, and smoking. Capillary length in
52 participants medicated for arterial hypertension ($n=20/61$) did not differ from participants
53
54
55
56
57
58
59
60

1
2
3 without hypertension. Participants treated with lipid lowering drugs with dyslipidemia
4 (n=10/61) also showed a trend for a higher capillary length than participants without
5 dyslipidemia (p=.079). Finally, there were no capillaroscopic difference between smokers and
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

without hypertension. Participants treated with lipid lowering drugs with dyslipidemia (n=10/61) also showed a trend for a higher capillary length than participants without dyslipidemia (p=.079). Finally, there were no capillaroscopic difference between smokers and non smokers. However, smokers who had been exposed to VCM tended to have a higher capillary length than non smokers (p=.073).

DISCUSSION

Principal findings of the study

Changes in microcirculation persist for at least 15 years following occupational VCM exposure, with a time-related exposure response. Symptoms of Raynaud, although statistically associated with exposure, was not related to pathological capillaroscopic changes.

What the study adds

The microcirculation changes following VCM exposure has been previously shown on 15 workers who ceased their occupational exposure six months prior to testing.¹³ Our study supports these results over a longer period following VCM exposure – 15 years.

The dose responsiveness of VCM exposure and compromised capillarisation is generally,¹³ but not always,¹² reported. Although daily VCM doses may have been more informative, the current study was restricted to years of exposure. Thus, we are limited to describing associations with an exposure time – response rather than a dose-response. Years of exposure is an easy question for physicians to ask of workers during risk assessment protocols.

The absence of changes in microcirculation on less exposed workers²⁹ resulted in a suggestion that a threshold of exposure exists. This finding is supported by previous studies showing that

1
2
3 long-term exposure (>8 years) induced greater chromosomal aberrations.^{10 30} Further, not all
4
5 workers exposed to VCM develop microvascular abnormalities, suggestive of an underlying
6
7 genetic susceptibility (polymorphism of glutathione S-transferase).^{5 11} A finding that female
8
9 VCM-exposed workers were more susceptible than males to the risk of increased
10
11 chromosome damage also reinforced genetic susceptibility theory.³⁰
12
13

14 15 16 **Comparison with other studies**

17
18 After 50 years of age, minor dystrophies could alter readability and interpretation of
19
20 capillaroscopic analyses.³¹ Nevertheless, we controlled this parameter by matching the
21
22 exposed group and the controls on age and we conducted a double-blind analysis by two
23
24 experienced readers. Moreover, capillaroscopic abnormalities among workers exposed to
25
26 VCM in the present study were not influenced by age.¹³
27
28

29
30 VCM has been suspected of causing respiratory and circulatory diseases.³² However, similar
31
32 frequencies of these diseases in both groups do not support this hypothesis.

33
34 Diabetes mellitus,¹⁶⁻²¹ high blood pressure,^{18 33-35} dyslipidemia,³⁴ or some
35
36 comorbidities/medications²² could interfere with microcirculation. In line with previous
37
38 studies, we showed a diminished capillary length in participants treated for arterial
39
40 hypertension,^{18 33-35} and a trend for participants treated with lipid lowering drugs.³⁴ Diabetes
41
42 mellitus was an exclusion criterion and thus, could not interfere with our results. Perhaps due
43
44 to low numbers of participants, our results failed to support previous findings of compromised
45
46 microcirculation in people with high blood pressure. The trend for increased capillary length
47
48 observed in our participants with dyslipidemia could be a response to increased peripheral
49
50 vascular resistance, in order to maintain their function of metabolic exchange.³⁵ Similarly,
51
52 smoking could induce a decrease in tissue perfusion,³⁶ and dystrophia.³⁷ We did not observe
53
54 differences between smokers and non-smokers, with the exception of a trend for abnormal
55
56
57
58
59
60

1
2
3 microcirculation among smokers exposed to VCM. The potential of a synergistic effect of
4 tobacco and VCM-exposure warrants further investigations. It should be noted that VCM
5 exposure in the current study was more strongly associated with compromised
6 microcirculation than high blood pressure, dyslipidemia and smoking.
7
8

9
10
11 Previous research into the links between systemic sclerosis and VCM exposure is limited by
12 single case design³⁸ and somewhat dated analyses of a population exposed to solvents.³⁹ The
13 broader use of term such as solvents is less specific than the VCM exposure carefully isolated
14 for investigation in the present study.
15
16

17
18
19 A higher prevalence of symptoms of Raynaud has been established in workers with VCM
20 exposure,³² up to one third of the exposed workers.¹³ The comparison between studies with
21 different selection criteria and different sample sizes is difficult. There is also the possibility
22 of selection bias in non randomized recruitment. Within these limitations, our results support
23 previous data, and extend knowledge by demonstrating the prevalence of symptoms of
24 Raynaud remained higher at least 15 years following VCM exposure. Furthermore, in the
25 current study, all the participants who suffered from symptoms of Raynaud had never taken
26 medications or suffered from other diseases conducive to Raynaud.
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Unanswered questions**

42
43 Although symptoms of Raynaud are statistically associated with VCM exposure, we could not
44 report a link with capillaroscopic modifications. The pathophysiology of Raynaud's
45 phenomenon remains unknown. There seems to be primary or secondary vascular failure
46 influenced by a hereditary factor.⁴⁰ Decreased perfusion pressure could be secondary to
47 systemic hypotension or be caused by proximal arterial occlusion, influenced by many
48 factors; both vascular and intra vascular, neural, environmental or hereditary.⁴¹ Angiography
49 of the hands of patients exposed to VCM showed occlusions, stenosis and narrowing of distal
50
51
52
53
54
55
56
57
58
59
60

1
2
3 arteries with the development of collateral circulation.⁴² Lack of statistical power in our study
4
5 could contribute to the lack of relationship between capillaroscopic changes and symptoms of
6
7 Raynaud.
8
9

10 11 12 **Strengths and limitations of study**

13
14 This study presents some major strengths: a rigorous selection criteria of exclusively VCM
15
16 exposed participants avoided confounding factors, well-matched controls, a double blind
17
18 analyses, sufficient number of participants to detect the capillaroscopic differences between
19
20 groups, the focus on retired workers at least 15 years after the end of occupational VCM
21
22 exposure. The attendance rate of 30% (53 of 179 individuals exclusively exposed to VCM at
23
24 work agreed to participate in our study) seems very high compared with other studies⁴³⁻⁴⁷
25
26 taking into account their age (75 years), distance from the location of the medical examination
27
28 (averaging approximately 80 km), and that no financial compensation was offered.
29

30
31 There are limitations to this study: a cross-sectional design however, proof of concept was
32
33 important and achieved (with a possibility of longitudinal follow-up); differences in some but
34
35 not all capillary outcomes may be explained by a lack of power; the results are insufficient to
36
37 propose guidelines for all workers exposed to VCM; more accurate quantifiable measures of
38
39 VCM exposure are not available, however for the purpose of this study we used industry
40
41 established lists of exposure legally required in France; we combined our knowledge only use a
42
43 binary pathophysiology of Raynaud after VCM exposure remains unclear, most of the retired
44
45 workers exposed to VCM were from the same enterprise; and potentially more at-risk
46
47 manufacturing processes remained undetected.
48
49
50
51

52 53 54 55 56 57 **CONCLUSION**

1
2
3 Although VCM exposure was already known to affect microcirculation, our study
4
5 demonstrated the potential for residual long-term abnormalities following an average of 15
6
7 years retirement, with a time exposure – response. Symptoms of Raynaud, although
8
9 statistically associated with exposure were not associated with capillaroscopic modifications;
10
11 its origin remains to be determined. Future research could focus on other chemical products
12
13 which have a similar structure than VCM and more extensive research on type of occupations
14
15 at-risk of VCM exposure.
16
17
18
19
20
21
22

23 **Role of the Funding Source**

24
25 The Occupational Medicine department of CHU G. Montpied, Clermont-Ferrand, France
26
27 funded this study. No other funding source had a role in the design, conduct, or reporting of
28
29 the study.
30
31
32
33

34 **Contributors**

35
36 VL has participated as a MD student and principal investigator. FD and AC obtained research
37
38 funding and generated the intellectual development of the study. FD knew potential exposed
39
40 workers to VCM. VL, FD, AC and SH contributed to the conception of the protocol. VL, FD
41
42 and SH made data analysis. VL, FD, MT contributed to manuscript drafting. VL recruited all
43
44 participants and performed all capillaroscopies. VL and MT completed the double blind
45
46 analyses of capillaroscopy. FD, AC, VL, GN and MT revised the manuscript. All authors read
47
48 and approved the final manuscript.
49
50
51
52
53

54 **Acknowledgments**

55
56
57
58
59
60

Our thanks to Geraldine Naughton for help with manuscript English proof reading. We also want to acknowledge the “Association of the sick from chemicals” (Association des Malades de la Chimie), 15 Av Albert Poncet 03410 Domerat, France, which helped us recruit the retired workers from VCM exposure.

REFERENCES

- 1 Allsopp M, Giovanni G. Poly(Vinyl Chloride) *Ullmann's Encyclopedia of Industrial Chemistry* 2000.
- 2 Fontana L, Baietto M, Becker F, Catilina P. [Clinical and capillaroscopic study of Raynaud's phenomenon in retired patients previously exposed to vinyl chloride monomer]. *J Mal Vasc* 1995;20:268-73.
- 3 Veltman G, Lange CE, Juhe S, Stein G, Bachner U. Clinical manifestations and course of vinyl chloride disease. *Ann N Y Acad Sci* 1975;246:6-17.
- 4 Harris DK, Adams WG. Acro-osteolysis occurring in men engaged in the polymerization of vinyl chloride. *Br Med J* 1967;3:712-4.
- 5 Fontana L, Marion MJ, Ughetto S, Catilina P. Glutathione S-transferase M1 and GST T1 genetic polymorphisms and Raynaud's phenomenon in French vinyl chloride monomer-exposed workers. *J Hum Genet* 2006;51:879-86.
- 6 Preston BJ, Jones KL, Grainger RG. Clinical aspects of vinyl chloride disease: acro-osteolysis. *Proc R Soc Med* 1976;69:284-6.
- 7 Wilson RH, McCormick WE, Tatum CF, Creech JL. Occupational acroosteolysis. Report of 31 cases. *JAMA* 1967;201:577-81.
- 8 Dragani TA, Zocchetti C. Occupational exposure to vinyl chloride and risk of hepatocellular carcinoma. *Cancer Causes Control* 2008;19:1193-200.
- 9 Mundt KA, Dell LD, Austin RP, Luippold RS, Noess R, Bigelow C. Historical cohort study of 10 109 men in the North American vinyl chloride industry, 1942-72: update of cancer mortality to 31 December 1995. *Occup Environ Med* 2000;57:774-81.
- 10 Kumar AK, Balachandar V, Arun M et al. A Comprehensive Analysis of Plausible Genotoxic Covariates Among Workers of a Polyvinyl Chloride Plant Exposed to Vinyl Chloride Monomer. *Arch Environ Contam Toxicol* 2012.
- 11 Ji F, Zhu S, Sun P, Wang W. [Relationship between genetic polymorphisms of phase I and phase II metabolizing enzymes and DNA damage of workers exposed to vinyl chloride monomer]. *Wei Sheng Yan Jiu* 2009;38:7-11.
- 12 Langauer-Lewowicka H. Nailfold capillary abnormalities in polyvinyl chloride production workers. *Int Arch Occup Environ Health* 1983;51:337-40.
- 13 Maricq HR, Darke CS, Archibald RM, Leroy EC. In vivo observations of skin capillaries in workers exposed to vinyl chloride. An English-American comparison. *Br J Ind Med* 1978;35:1-7.
- 14 Maricq HR, Johnson MN, Whetstone CL, LeRoy EC. Capillary abnormalities in polyvinyl chloride production workers. Examination by in vivo microscopy. *JAMA* 1976;236:1368-71.


- 1
2
3 15 Kowal-Bielecka O, Bielecki M, Kowal K. Recent advances in the diagnosis and
4 treatment of systemic sclerosis. *Polskie Archiwum Medycyny Wewnętrznej*
5 2013;123:51-8.
- 6 16 Pazos-Moura CC, Moura EG, Bouskela E, Torres Filho IP, Breitenbach MM. Nailfold
7 capillaroscopy in non-insulin dependent diabetes mellitus: blood flow velocity during
8 rest and post-occlusive reactive hyperaemia. *Clin Physiol* 1990;10:451-61.
- 9 17 Iabichella ML, Mariotti R, Nuti M, Balbarini A, Mariani M. [Site specificity of
10 biomicroscopic pattern in diabetic patients]. *Minerva Cardioangiol* 1999;47:619-21.
- 11 18 Lambova SN, Muller-Ladner U. The specificity of capillaroscopic pattern in
12 connective autoimmune diseases. A comparison with microvascular changes in
13 diseases of social importance: arterial hypertension and diabetes mellitus. *Mod*
14 *Rheumatol* 2009;19:600-5.
- 15 19 Vayssairat M, Le Devehat C. [Critical analysis of vascular explorations in diabetic
16 complications]. *J Mal Vasc* 2001;26:122-5.
- 17 20 Meyer MF, Pfohl M, Schatz H. [Assessment of diabetic alterations of microcirculation
18 by means of capillaroscopy and laser-Doppler anemometry]. *Med Klin (Munich)*
19 2001;96:71-7.
- 20 21 Chang CH, Tsai RK, Wu WC, Kuo SL, Yu HS. Use of dynamic capillaroscopy for
21 studying cutaneous microcirculation in patients with diabetes mellitus. *Microvasc Res*
22 1997;53:121-7.
- 23 22 Gallucci F, Russo R, Buono R, Acampora R, Madrid E, Uomo G. Indications and
24 results of videocapillaroscopy in clinical practice. *Adv Med Sci* 2008;53:149-57.
- 25 23 Hern S, Mortimer PS. Visualization of dermal blood vessels--capillaroscopy. *Clin Exp*
26 *Dermatol* 1999;24:473-8.
- 27 24 Ingegnoli F, Gualtierotti R, Lubatti C et al. Feasibility of different capillaroscopic
28 measures for identifying nailfold microvascular alterations. *Seminars in Arthritis and*
29 *Rheumatism* 2009;38:289-95.
- 30 25 Kabasakal Y, Elvins DM, Ring EF, McHugh NJ. Quantitative nailfold capillaroscopy
31 findings in a population with connective tissue disease and in normal healthy controls.
32 *Ann Rheum Dis* 1996;55:507-12.
- 33 26 Bhakuni DS, Vasdev V, Garg MK, Narayanan K, Jain R, Mullick G. Nailfold
34 capillaroscopy by digital microscope in an Indian population with systemic sclerosis.
35 *Int J Rheum Dis* 2012;15:95-101.
- 36 27 Cutolo M, Pizzorni C, Secchi ME, Sulli A. Capillaroscopy. *Best Pract Res Clin*
37 *Rheumatol* 2008;22:1093-108.
- 38 28 Jouanny P, Schmidt C, Feldmann L, Schmitt J. [Focus on a quick reading of nailfold
39 capillaroscopy]. *Journal des Maladies Vasculaires* 1994;19:206-9.
- 40 29 Przybylowski J, Podolecki A, Laks L et al. [Health status of workers in polyvinyl
41 chloride processing plants. I. Evaluation of occupational exposure. Subjective and
42 capillaroscopy studies. Conduction velocity in the motor nerves]. *Med Pr*
43 1983;34:385-96.
- 44 30 Jiao J, Feng NN, Li Y et al. Estimation of a Safe Level for Occupational Exposure to
45 Vinyl Chloride Using a Benchmark Dose Method in Central China. *J Occup Health*
46 2012.
- 47 31 Carpentier PH. New techniques for clinical assessment of the peripheral
48 microcirculation. *Drugs* 1999;59 Spec No:17-22.
- 49 32 Laplanche A, Clavel F, Contassot JC, Lanuziere C. Exposure to vinyl chloride
50 monomer: report on a cohort study. *Br J Ind Med* 1987;44:711-5.
- 51 33 Prasad A, Dunnill GS, Mortimer PS, MacGregor GA. Capillary rarefaction in the
52 forearm skin in essential hypertension. *J Hypertens* 1995;13:265-8.
- 53
54
55
56
57
58
59
60

- 1
2
3 34 Bonacci E, Santacroce N, D'Amico N, Mattace R. Nail-fold capillaroscopy in the
4 study of microcirculation in elderly hypertensive patients. *Arch Gerontol Geriatr*
5 1996;22 Suppl 1:79-83.
- 6 35 Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Structural
7 skin capillary rarefaction in essential hypertension. *Hypertension* 1999;33:998-1001.
- 8 36 Lehr HA. Microcirculatory dysfunction induced by cigarette smoking.
9 *Microcirculation* 2000;7:367-84.
- 10 37 Lova RM, Miniati B, Macchi C et al. Morphologic changes in the microcirculation
11 induced by chronic smoking habit: a videocapillaroscopic study on the human labial
12 mucosa. *Am Heart J* 2002;143:658.
- 13 38 Betta A, Tommasini M, Bovenzi M, Barbone F, Versini W, Romeo L. [Scleroderma
14 and occupational factors: a case-control study and analysis of literature]. *Medicina del*
15 *Lavoro* 1994;85:496-506.
- 16 39 Ostlere LS, Harris D, Buckley C, Black C, Rustin MH. Atypical systemic sclerosis
17 following exposure to vinyl chloride monomer. A case report and review of the
18 cutaneous aspects of vinyl chloride disease. *Clinical and Experimental Dermatology*
19 1992;17:208-10.
- 20 40 Block JA, Sequeira W. Raynaud's phenomenon. *Lancet* 2001;357:2042-8.
- 21 41 Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. *Nat*
22 *Rev Rheumatol* 2012;8:469-79.
- 23 42 Koischwitz D, Marsteller HJ, Lackner K, Brecht G, Brecht T. [Changes in the arteries
24 in the hand and fingers due to vinyl chloride exposure (author's transl)]. *Rofo*
25 1980;132:62-8.
- 26 43 Dutheil F, Kelly C, Biat I et al. [Relation between the level of knowledge and the rate
27 of vaccination against the flu virus among the staff of the Clermont-Ferrand
28 University hospital]. *Med Mal Infect* 2008;38:586-94.
- 29 44 Chiew M, Weber MF, Egger S, Sitas F. A cross-sectional exploration of smoking
30 status and social interaction in a large population-based Australian cohort. *Social*
31 *Science and Medicine* 2012;75:77-86.
- 32 45 Penforis A, San-Galli F, Cimino L, Huet D. Current insulin therapy in patients with
33 type 2 diabetes: results of the ADHOC survey in France. *Diabetes and Metabolism*
34 2011;37:440-5.
- 35 46 Heinavaara S, Tokola K, Kurttio P, Auvinen A. Validation of exposure assessment
36 and assessment of recruitment methods for a prospective cohort study of mobile phone
37 users (COSMOS) in Finland: a pilot study. *Environ Health* 2011;10:14.
- 38 47 Eriksen L, Gronbaek M, Helge JW, Tolstrup JS, Curtis T. The Danish Health
39 Examination Survey 2007-2008 (DANHES 2007-2008). *Scand J Public Health*
40 2011;39:203-11.
- 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Table 1 Characteristics of participants, exposure to VCM and capillaroscopic outcomes.

	Retired from exposure to VCM (n=21)	Controls (n=40)	p- value
Age – years	74.4±2.9	76.3±3.2	NS
type of occupation: blue collar workers – “manual”	100%	100%	NS
Exposure to VCM:			
direct contact with VCM	100%	0	<.001
exposure time – years	29.8±1.9	0	<.001
time after exposure – years	15.9±2.4	-	-
Main capillaroscopic outcomes:			
1. density			
mean density – mm	8.6±0.4	8.8±0.3	NS
decreased capillary density <10/mm – n (%)	9 (43)	16 (46)	NS
avascular zone <7/mm – n(%)	0	0	NS
2. length			
mean length – µm	291±14	254±9	.020
augmented capillary length >300µm – n(%)	7 (33)	0	<.001
3. diameter			
mean diameter of capillaries – µm	28.9±0.9	25.7±0.6	.006
enlarged capillaries >25µm – n(%)	4 (19)	0	<.001
megacapillary >50µm – n(%)	0	0	NS
4. dystrophy			
capillary branching >15% – n(%)	6 (29)	0	<.001
5. hemorrhage – n(%)			
	0	0	NS
Symptoms of Raynaud:			
n(%) with Raynaud	4 (19)	0	.007
Participants with medications which could induce Raynaud – n(%)	2 (9)	4 (11)	NS
Other causes of Raynaud	0	0	NS
Comorbidities			
Respiratory diseases	2 (9)	6 (17)	NS
Cardiovascular diseases (except high blood pressure)	4 (19)	5 (14)	NS
Myocardial infraction	3 (14)	3(9)	NS
Routine medications – n(%) of patients treated for:			
Blood pressure	7 (33)	13 (37)	NS
Lipid lowering	4 (19)	6 (17)	NS
Smoking – n(%)	9 (43)	18 (51)	NS

Figure 1 Participant flow chart.



1
2
3 **Figure 2** Normal capillaroscopy on a control participant (A) and capillaroscopy with
4 dystrophia >15% in a retired worker exposed to VCM for 37 years, with no treatment and no
5 comorbidity, non smoking (B).
6
7
8
9



1
2
3
4
5
6
7 **The long-term effects of occupational exposure to vinyl chloride monomer**
8
9 **on microcirculation: a cross-sectional study 15 years after retirement**
10

11
12
13
14
15 Vincent Lopez ¹, Alain Chamoux ¹, Marion Tempier ², H el ene Thiel ³, Sylvie Ughetto ⁴,
16
17 Marion Trousselard ⁵, Geraldine Naughton ⁶, Fr ed eric Dutheil ^{1,6,7,*}
18
19

20
21 ¹ Occupational Medicine, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand,
22
23 France
24

25 ² Radiopharmacy, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand, France
26

27 ³ Vascular Medicine, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand,
28
29 France
30

31 ⁴ Department of Medical Information - Clinical research and innovation direction, University
32
33 Hospital CHU G. Montpied, 63000 Clermont-Ferrand, France
34

35 ⁵ Neurophysiology of emotions, ENOP department, CRSSA/IRBA, 38702 La Tronche,
36
37 France
38

39 ⁶ School of Exercise Science, Australian Catholic University, Locked Bag 4115 Fitzroy MDC
40
41 VIC 3065, Australia
42

43 ⁷ Laboratory of Metabolic Adaptations to Exercise in Physiological and Pathological
44
45 conditions (AME2P, EA3533), 63000 Clermont-Ferrand, France
46
47

48 ***Correspondance to** Fr ed eric Dutheil, Occupational Medicine, University Hospital CHU G.
49
50 Montpied, 63000 Clermont-Ferrand, France Tel: +33 6 88 22 48 48. Fax: +33 4 73 27 46 49.
51
52 fred_dutheil@yahoo.fr.
53
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Running Title: Capillaroscopy post-exposure to VCM


Words count for introduction methods results discussion conclusion: 2298

Number of tables: 1

Number of figures: 2

Words count for abstract: 258

For peer review only



ABSTRACT

Objectives: To assess residual long-term microcirculation abnormalities by capillaroscopy, 15 years after retiring from occupational exposure to vinyl chloride monomer (VCM).

Design: Cross-sectional study.

Setting: Allier, one of the major area of PVC production in France.

Participants: We ~~screened~~ ~~enrolled~~ 761 (97% males) ~~male~~ retired workers exposed to chemical toxics. Exposure to chemical other than VCM excluded potential participants.

Primary and secondary outcomes measures: These participants underwent a medical examination including a capillaroscopy, symptoms of Raynaud, and comorbidities, as well as a survey to determine exposure time, direct or indirect contact, type of occupation, smoking status and time after exposure. A double blind analysis of capillaroscopic images was done. A control group was matched in age, sex, type of occupation.


Results: 179/761 retired workers were only exposed to VCM at their work, with 21 meeting the inclusion criteria and included. Exposure time was 29.8 ± 1.9 years and time after exposure was 15.9 ± 2.4 years. Retired workers previously exposed to VCM had significantly higher capillaroscopic modifications than 35 controls: enlarged capillaries (19% vs. 0%, $p < .001$), dystrophy (28.6% vs. 0%, $p = .0012$), and augmented length (33% vs. 0%, $p < .001$). Time exposure was linked with enlarged capillaries (R^2 adjusted = 63.53%, $p < .0001$). They also had higher symptoms of Raynaud (19% vs. 0%, $p = .007$) without correlation with capillaroscopic modifications.

Conclusion: Although VCM exposure was already known to affect microcirculation, our study demonstrates residual long term abnormalities following an average of 15 years retirement, with a time-related exposure response. Symptoms of Raynaud, although statistically associated with exposure was not related to capillaroscopic modifications; its origin remains to be determined.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords Exposition, Vinyl chloride monomer, Capillaroscopy, Raynaud

For peer review only



ARTICLE SUMMARY**Article focus**

- Vinyl chloride monomer exposure induces microcirculation abnormalities, which can be diagnosed by capillaroscopy.
- Residual long-term abnormalities following retirement required investigation.

Key messages

- Our results demonstrated residual long-term abnormalities following an average of 15 years retirement, with a time-related exposure response.
- Symptoms of Raynaud, although statistically associated with exposure, was not related to capillaroscopic modifications; its origin remains to be determined.

Strengths and limitations of this study

- The strong points is that this study had a rigorous selection criteria of exclusively VCM exposed participants avoided confounding factor and the focus on retired workers at least 15 years after the end of occupational VCM exposure.
- The main limitation is that pathophysiology of Raynaud after VCM exposure remains unclear.

INTRODUCTION

Vinyl chloride monomer (VCM) is primarily used in the manufacture of plastics and also serves as a raw material in organic synthesis. VCM is an aliphatic hydrocarbon also known as chloroethene. Its polymerization lead to a synthetic resin called polyvinyl chloride, commonly abbreviated PVC. PVC, is the third-most widely produced plastic, after polyethylene and polypropylene.¹ PVC can be made softer and more flexible by the addition of phthalates, and may also replace rubber. Thus, PVC is widely used including: pipes and water distribution, a substitute for painted wood (e.g. window frames, sills, flooring), electrical cable insulation, inflatable products, waterproof clothing (e.g. coats, skiing equipment, shoes), healthcare products (e.g. containers, tubing, catheters), food packaging, dental appliances and vinyl records.¹

Harmless in its polymeric form, workers handling the finished PVC product are perfectly safe.

In contrast, the at-risk phase lies in the manual descaling of autoclaves used for the polymerization where workers can contact it during its monomer state.² The chronic intoxication by gaseous monomer VCM is linked to several symptoms such as:³ asthenia and dizziness,³ Raynaud's syndrome,⁴ ⁵ digestive ulcers with nausea and anorexia,³ systemic symptoms of arthralgia and myalgia³, trophic cutaneous symptoms and sclerosis. It has also been suspected in the onset of acroosteolysis⁴ ⁶ ⁷ and hepatocellular carcinoma.⁸ ⁹ More generally, VCM exposure involves chromosomal aberrations and increased carcinogenic risk.¹⁰ Even if VCM related diseases may have a genetic bases, they are also linked to prolonged occupational VCM exposure.⁵ ¹¹

Scleroderma-like microvascular abnormalities have been also described on exposed workers.¹²⁻¹⁴ The most common and non-invasive means of investigating these abnormalities is capillaroscopy. Widespread identification of individuals most at risk could enable early detection and management strategy~~treatment~~.¹⁵ The residual effects of VCM on

1
2
3
4
5
6
7 microcirculation have been shown only once on 15 workers who had ceased their VCM
8 exposure six months prior to testing.¹³ However, residual long-term abnormalities following
9 retirement are unknown. Our hypothesis was higher capillaroscopic abnormalities in the VCM
10 exposed group than in the control group.
11

12
13
14 Therefore, the aim of our cross-sectional study was to investigate residual long-term
15 capillaroscopic abnormalities following retirement, after 15 years without VCM exposure.
16
17

18 19 20 21 22 **METHODS**

23 24 **Participants**

25
26 We enrolled male retired workers exposed to VCM in PVC production. They provided written
27 informed consent. The study was approved by the human ethics committees from Clermont-
28 Ferrand university hospital, France. To be eligible, participants had to be: male (due to male
29 dominance in this workforce), retired, aged over 60 years, with at least a 5-year occupational
30 exposure to VCM, a time after VCM exposure of at least 5 years, and no exposure to
31 chemicals other than VCM. Moreover, participants with diabetes mellitus were also excluded
32 as it may interfere with microcirculation,¹⁶⁻²¹ as well as individuals declaring the use or
33 previous use of treatments which may alter microcirculation.
34
35
36
37
38
39
40

41
42 Participants responded to a survey to determine exposure time, direct or indirect contact, type
43 of occupation, time after exposure and smoking history. They underwent a medical
44 examination including a capillaroscopy, symptoms of Raynaud, and comorbidities such as
45 pathologies that may interfere with microcirculation (arterial hypertension, dyslipidemia) or
46 pathologies potentially linked with VCM exposure (cardiovascular or respiratory diseases).²²
47
48
49
50
51
52
53
54
55
56

1
2
3
4
5
6
7 A control group was matched in age, sex, type of occupation. They were recruited via
8 advertisements. Selection criteria for this group also included no occupational or leisure
9 chemical exposure, and no diabetes mellitus.¹⁶⁻²¹

Field Code Changed

14 15 **Capillaroscopy**

16 A nailfold capillaroscopy was performed on all fingers of each patient, excluding thumbs.²³

Field Code Changed

17 The nailfold capillaroscopies of the fingers were captured in images and electronically stored.

18 The same investigator conducted all the capillaroscopies. A double blind analysis of
19 capillaroscopic images was completed on deidentified data.

20 The outcomes were the five following classical criteria used in capillaroscopy:²³ density,
21 length, diameter, dystrophy and hemorrhage. Criteria for abnormalities were defined as:
22 decreased capillary density <10/mm (avascular zone <7/mm),²⁴ augmented capillary length
23 >300µm,²⁴ ²⁵—increased capillary diameter >2530µm²⁵ (megacapillary >50µm)²⁶ ²⁷, and
24 dystrophy was associated with capillary branching >15%.²⁸ Hemorrhage is defined as the
25 microvascular extravasation of the red blood cells linked to the damage of the vessel wall.²⁷

Formatted: Font: Not Italic

38 **Statistics**

39 Data are presented as mean percentage change and standard deviation (SD).

40 The main judgment criterion for abnormal microcirculation was the presence of at least one
41 abnormality in capillaroscopy. The most common abnormality is capillary dystrophy.²⁵

42 Previous data² ²⁵ and personal observation on residual long-term abnormalities following
43 VCM exposure showed that a percentage of dystrophy of approximately 25% was required to
44 differentiate between the exposed group and the controls. Using this value as the main
45 outcome, we calculated that a sample of 10 participants per group allows a statistical power
46 greater than 80% with an alpha level less than 5%.

1
2
3
4
5
6
7 Statistical analyses were performed with SPSS software, v19. Correlations were used for
8 inter-observer reliability. The Gaussian distribution for each parameter was assessed by a
9
10 Shapiro-Wilk test. Comparisons between groups (exposed vs. control) were made through the
11
12 usual tests: Chi2 test for categorical variables (or Fisher's exact test where appropriate) and
13
14 Student's t test for quantitative variables (or Kruskal-Wallis if assumptions of normal
15
16 distribution were violated). Significance was accepted for a p-value < 5%. A matrix of the
17 correlations between the outcomes and exposure was determined using a non-parametric
18 Spearman test. The links between continuous variables were analyzed using linear regression.
19
20 The links between b-inary and continuous variables were analyzed with logistic regression.
21
22
23
24 Multivariate models were used to predict the relationship between capillary parameters and
25
26 other parameters such as exposure time and time after exposure.
27
28
29
30
31

Formatted: Highlight

32 RESULTS

33 34 35 Participants

36
37 We screened enrolled-761 (97% males) retired workers exposed to chemical toxics from two
38
39 leading enterprises involved in PVC production (n=435 and n=91), as well as participants
40
41 from many subcontracting companies (n=235), also known for VCM exposure. The strict
42
43 selection criteria of exposure only to VCM reduced the sample size to 21 (figure 1).
44

45 Thirty five age-matched controls were also recruited without occupational or leisure time
46
47 exposure to chemical toxics.
48

49 50 Main capillaroscopic outcomes

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

There was no missing data. ~~Double blinded analysis showed no statistical difference between the two investigators.~~ Inter-rater reliability was confirmed with correlations exceeding 0.70 for each parameter. The mean of the values of the 2 investigators is presented in table 1. Concerning the qualitative data, when a disagreement occurred, the two observers analyzed again together and requested the opinion of a third expert. The disagreement occurred only for 2 decreased capillary density <10/mm, and 1 capillary branching >15%.

Compared with controls, retired workers previously exposed to VCM had higher capillaroscopic abnormalities: enlarged capillaries (0% vs. 19%, $p<.001$), dystrophy (0% vs. 28.6%, $p=.0012$) (figure 2), and augmented length (0% vs. 33%, $p<.001$). The mean length was 15% higher in the exposed group than in controls ($291\pm 14\mu$ vs. $254\pm 9\mu$, $p=.020$), as well as a 12% greater the mean diameter of capillaries ($28.9\pm 0.9\mu$ vs. $25.7\pm 0.6\mu$, $p=.006$) (table 1).

Exposure

Exposure time was 29.8 ± 1.9 years and time after exposure was 15.9 ± 2.4 years. Time of exposure to VCM was strongly linked with enlarged capillaries (R^2 adjusted = ~~63.53%~~, $p<.0001$) and modestly linked with capillary length (R^2 ~~adjusted~~ = 8%; $p=.031$) (table 1). Age was not associated with capillaroscopic abnormalities. No multivariate models improved results from simple regressions.

Symptoms of Raynaud

VCM exposed group also had more symptoms of Raynaud (19% vs. 0%, $p=.007$) independent of capillaroscopic modifications (table 1).

Comorbidities and smoking

Neither respiratory nor cardiovascular diseases were associated with VCM exposure. However, we combined both groups to explore potential associations between capillaroscopic parameters and high blood pressure, dyslipidemia, and smoking. Capillary length in participants medicated for arterial hypertension (n=20/61) did not differ from participants without hypertension. Participants treated with lipid lowering drugs with dyslipidemia (n=10/61) also showed a trend for a higher capillary length than participants without dyslipidemia (p=.079). Finally, there were no capillaroscopic difference between smokers and non smokers. However, smokers who had been exposed to VCM tended to have a higher capillary length than non smokers (p=.073).

DISCUSSION

Principal findings of the study

Changes in microcirculation persist for at least 15 years following occupational VCM exposure, with a time-related exposure response. Symptoms of Raynaud, although statistically associated with exposure, was not related to pathological capillaroscopic changes.

What the study adds

The microcirculation changes following VCM exposure has been previously shown on 15 workers who ceased their occupational exposure six months prior to testing.¹³ Our study supports these results over a longer period following VCM exposure – 15 years.

The dose responsiveness of VCM exposure and compromised capillarisation is generally,¹³ but not always,¹² well reported~~accepted~~.¹³ Although daily VCM doses may have been more

Field Code Changed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

informative, the current study was restricted to years of exposure. Thus, we are limited to describing associations with an exposure time – response rather than a dose-response. Years of exposure is an easy question for physicians to ask of workers during risk assessment protocols.

Formatted: Not Highlight

Formatted: Not Highlight

The absence of changes in microcirculation on less exposed workers²⁹ resulted in a suggestion that a threshold of exposure exists. This finding is supported by previous studies showing that long-term exposure (>8 years) induced greater chromosomal aberrations.^{10 30} Further, not all workers exposed to VCM develop microvascular abnormalities, suggestive of an underlying genetic susceptibility (polymorphism of glutathione S-transferase).^{5 11} A finding that female VCM-exposed workers were more susceptible than males to the risk of increased chromosome damage also reinforced genetic susceptibility theory.³⁰

Comparison with other studies

After 50 years of age, minor dystrophies could alter readability and interpretation of capillaroscopic analyses.³¹ Nevertheless, we controlled this parameter by matching the exposed group and the controls on age and we conducted a double-blind analysis by two experienced readers. Moreover, capillaroscopic abnormalities among workers exposed to VCM in the present study were not influenced by age.¹³

Field Code Changed

VCM has been suspected of causing respiratory and circulatory diseases.³² However, similar frequencies of these diseases in both groups do not support this hypothesis.

Field Code Changed

Field Code Changed

Diabetes mellitus,¹⁶⁻²¹ high blood pressure,^{18 33-35} dyslipidemia,³⁴ or some comorbidities/medications²² could interfere with microcirculation. In line with previous studies, we showed a diminished capillary length in participants treated for arterial hypertension,^{18 33-35} and a trend for participants treated with lipid lowering drugs.³⁴ Diabetes mellitus was an exclusion criterion and thus, could not interfere with our results. Perhaps due

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

1
2
3
4
5
6
7 to low numbers of participants, our results failed to support previous findings of compromised
8 microcirculation in people with high blood pressure. The trend for increased capillary length
9 observed in our participants with dyslipidemia could be a response to increased peripheral
10 vascular resistance, in order to maintain their function of metabolic exchange.³⁵ Similarly,
11 smoking could induce a decrease in tissue perfusion,³⁶ and dystrophia.³⁷ We did not observe
12 differences between smokers and non-smokers, with the exception of a trend for abnormal
13 microcirculation among smokers exposed to VCM. The potential of a synergistic effect of
14 tobacco and VCM-exposure warrants further investigations. It should be noted that VCM
15 exposure in the current study was more strongly associated with compromised
16 microcirculation than high blood pressure, dyslipidemia and smoking.
17
18
19
20
21
22
23
24
25

26 Previous research into the links between systemic sclerosis and VCM exposure is limited by
27 single case design³⁸ and somewhat dated analyses of a population exposed to solvents.³⁹ The
28 broader use of term such as solvents is less specific than the VCM exposure carefully isolated
29 for investigation in the present study.
30
31
32

33 AA higher prevalence of symptoms of Raynaud has been established in workers with VCM
34 exposure,³² up to one third of the exposed workers.¹³ The comparison between studies with
35 different selection criteria and different sample sizes is difficult. There is also the possibility
36 of selection bias in non randomized recruitment. Within these limitations, o
37 Our results
38 support previous these data, and extend knowledge by demonstrating the prevalence of
39 symptoms of Raynaud remained higher at least 15 years following VCM exposure.
40
41 Furthermore, in the current study, all the participants who suffered from symptoms of
42 Raynaud had never taken medications or suffered from other diseases conducive to Raynaud.
43
44
45
46
47
48
49
50

51 **Unanswered questions**

52
53
54
55
56
57
58
59
60

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

1
2
3
4
5
6
7 Although symptoms of Raynaud are statistically associated with VCM exposure, we could not
8 report a link with capillaroscopic modifications. The pathophysiology of Raynaud's
9 phenomenon remains unknown. There seems to be primary or secondary vascular failure
10 influenced by a hereditary factor.⁴⁰ Decreased perfusion pressure could be secondary to
11 systemic hypotension or be caused by proximal arterial occlusion, influenced by many
12 factors; both vascular and intra vascular, neural, environmental or hereditary.⁴¹ Angiography
13 of the hands of patients exposed to VCM showed occlusions, stenosis and narrowing of distal
14 arteries with the development of collateral circulation.⁴² Lack of statistical power in our study
15 could contribute to the lack of relationship between capillaroscopic changes and symptoms of
16 Raynaud.
17
18
19
20
21
22
23
24
25
26
27

Field Code Changed

Field Code Changed

Field Code Changed

28 **Strengths and limitations of study**

29 This study presents some major strengths: a rigorous selection criteria of exclusively VCM
30 exposed participants avoided confounding factors, well-matched controls, a double blind
31 analyses, sufficient number of participants to detect the capillaroscopic differences between
32 groups, the focus on retired workers at least 15 years after the end of occupational VCM
33 exposure. The attendance rate of 30% (53 of 179 individuals exclusively exposed to VCM at
34 work agreed to participate in our study) seems very high compared with other studies⁴³⁻⁴⁷
35 taking into account their age (75 years), distance from the location of the medical examination
36 (averaging approximately 80 km), and that no financial compensation was offered.
37
38
39
40
41
42
43
44

45 There are limitations to this study: a cross-sectional design however, proof of concept was
46 important and achieved (with a possibility of longitudinal follow-up); differences in some but
47 not all capillary outcomes may be explained by a lack of power; the results are insufficient to
48 propose guidelines for all workers exposed to VCM; more accurate quantifiable measures of
49 VCM exposure are not available, however for the purpose of this study we used industry
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 established lists of exposure legally required in France; we combined our knowledge only use a
7
8 binary pathophysiology of Raynaud after VCM exposure remains unclear, most of the retired
9
10 workers exposed to VCM were from the same enterprise; and potentially more at-risk
11
12 manufacturing processes remained undetected.
13

14 15 16 17 18 19 **CONCLUSION**

20
21 Although VCM exposure was already known to affect microcirculation, our study
22
23 demonstrated the potential for residual long-term abnormalities following an average of 15
24
25 years retirement, with a time exposure – response. Symptoms of Raynaud, although
26
27 statistically associated with exposure were not associated with capillaroscopic modifications;
28
29 its origin remains to be determined. Future research could focus on other chemical products
30
31 which have a similar structure than VCM and more extensive research on type of occupations
32
33 at-risk of VCM exposure.
34
35
36
37
38

39 **Role of the Funding Source**

40 The Occupational Medicine department of CHU G. Montpied, Clermont-Ferrand, France
41
42 funded this study. No other funding source had a role in the design, conduct, or reporting of
43
44 the study.
45
46
47

48 **Contributors**

49 VL has participated as a MD student and principal investigator. FD and AC obtained research
50
51 funding and generated the intellectual development of the study. FD knew potential exposed
52
53 workers to VCM. VL, FD, AC and SH contributed to the conception of the protocol. VL, FD
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

and SH made data analysis. VL, FD, MT contributed to manuscript drafting. VL recruited all participants and performed all capillaroscopies. VL and MT completed the double blind analyses of capillaroscopy. FD, AC, VL, GN and MT revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

Our thanks to Geraldine Naughton for help with manuscript English proof reading. We also want to acknowledge the “Association of the sick from chemicals” (Association des Malades de la Chimie), 15 Av Albert Poncet 03410 Domerat, France, which helped us recruit the retired workers from VCM exposure.

REFERENCES

- 1 Allsopp M, Giovanni G. Poly(Vinyl Chloride) *Ullmann's Encyclopedia of Industrial Chemistry* 2000.
- 2 Fontana L, Baietto M, Becker F, Catilina P. [Clinical and capillaroscopic study of Raynaud's phenomenon in retired patients previously exposed to vinyl chloride monomer]. *J Mal Vasc* 1995;20:268-73.
- 3 Veltman G, Lange CE, Juhe S, Stein G, Bachner U. Clinical manifestations and course of vinyl chloride disease. *Ann N Y Acad Sci* 1975;246:6-17.
- 4 Harris DK, Adams WG. Acro-osteolysis occurring in men engaged in the polymerization of vinyl chloride. *Br Med J* 1967;3:712-4.
- 5 Fontana L, Marion MJ, Ughetto S, Catilina P. Glutathione S-transferase M1 and GST T1 genetic polymorphisms and Raynaud's phenomenon in French vinyl chloride monomer-exposed workers. *J Hum Genet* 2006;51:879-86.
- 6 Preston BJ, Jones KL, Grainger RG. Clinical aspects of vinyl chloride disease: acro-osteolysis. *Proc R Soc Med* 1976;69:284-6.
- 7 Wilson RH, McCormick WE, Tatum CF, Creech JL. Occupational acroosteolysis. Report of 31 cases. *JAMA* 1967;201:577-81.
- 8 Dragani TA, Zocchetti C. Occupational exposure to vinyl chloride and risk of hepatocellular carcinoma. *Cancer Causes Control* 2008;19:1193-200.
- 9 Mundt KA, Dell LD, Austin RP, Luippold RS, Noess R, Bigelow C. Historical cohort study of 10 109 men in the North American vinyl chloride industry, 1942-72: update of cancer mortality to 31 December 1995. *Occup Environ Med* 2000;57:774-81.
- 10 Kumar AK, Balachandar V, Arun M et al. A Comprehensive Analysis of Plausible Genotoxic Covariates Among Workers of a Polyvinyl Chloride Plant Exposed to Vinyl Chloride Monomer. *Arch Environ Contam Toxicol* 2012.

Formatted: French (France)

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 11 Ji F, Zhu S, Sun P, Wang W. [Relationship between genetic polymorphisms of phase I and phase II metabolizing enzymes and DNA damage of workers exposed to vinyl chloride monomer]. *Wei Sheng Yan Jiu* 2009;38:7-11.
- 12 Langauer-Lewowicka H. Nailfolds capillary abnormalities in polyvinyl chloride production workers. *Int Arch Occup Environ Health* 1983;51:337-40.
- 13 Maricq HR, Darke CS, Archibald RM, Leroy EC. In vivo observations of skin capillaries in workers exposed to vinyl chloride. An English-American comparison. *Br J Ind Med* 1978;35:1-7.
- 14 Maricq HR, Johnson MN, Whetstone CL, LeRoy EC. Capillary abnormalities in polyvinyl chloride production workers. Examination by in vivo microscopy. *JAMA* 1976;236:1368-71.
- 15 Kowal-Bielecka O, Bielecki M, Kowal K. Recent advances in the diagnosis and treatment of systemic sclerosis. *Polskie Archiwum Medycyny Wewnętrznej* 2013;123:51-8.
- 16 Pazos-Moura CC, Moura EG, Bouskela E, Torres Filho IP, Breitenbach MM. Nailfold capillaroscopy in non-insulin dependent diabetes mellitus: blood flow velocity during rest and post-occlusive reactive hyperaemia. *Clin Physiol* 1990;10:451-61.
- 17 Iabichella ML, Mariotti R, Nuti M, Balbarini A, Mariani M. [Site specificity of biomicroscopic pattern in diabetic patients]. *Minerva Cardioangiol* 1999;47:619-21.
- 18 Lambova SN, Muller-Ladner U. The specificity of capillaroscopic pattern in connective autoimmune diseases. A comparison with microvascular changes in diseases of social importance: arterial hypertension and diabetes mellitus. *Mod Rheumatol* 2009;19:600-5.
- 19 Vayssairat M, Le Devehat C. [Critical analysis of vascular explorations in diabetic complications]. *J Mal Vasc* 2001;26:122-5.
- 20 Meyer MF, Pfohl M, Schatz H. [Assessment of diabetic alterations of microcirculation by means of capillaroscopy and laser-Doppler anemometry]. *Med Klin (Munich)* 2001;96:71-7.
- 21 Chang CH, Tsai RK, Wu WC, Kuo SL, Yu HS. Use of dynamic capillaroscopy for studying cutaneous microcirculation in patients with diabetes mellitus. *Microvasc Res* 1997;53:121-7.
- 22 Gallucci F, Russo R, Buono R, Acampora R, Madrid E, Uomo G. Indications and results of videocapillaroscopy in clinical practice. *Adv Med Sci* 2008;53:149-57.
- 23 Hern S, Mortimer PS. Visualization of dermal blood vessels--capillaroscopy. *Clin Exp Dermatol* 1999;24:473-8.
- 24 Ingegnoli F, Gualtierotti R, Lubatti C et al. Feasibility of different capillaroscopic measures for identifying nailfold microvascular alterations. *Seminars in Arthritis and Rheumatism* 2009;38:289-95.
- 25 Kabasakal Y, Elvins DM, Ring EF, McHugh NJ. Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. *Ann Rheum Dis* 1996;55:507-12.
- 26 Bhakuni DS, Vasdev V, Garg MK, Narayanan K, Jain R, Mullick G. Nailfold capillaroscopy by digital microscope in an Indian population with systemic sclerosis. *Int J Rheum Dis* 2012;15:95-101.
- 27 Cutolo M, Pizzorni C, Secchi ME, Sulli A. Capillaroscopy. *Best Pract Res Clin Rheumatol* 2008;22:1093-108.
- 28 Jouanny P, Schmidt C, Feldmann L, Schmitt J. [Focus on a quick reading of nailfold capillaroscopy]. *Journal des Maladies Vasculaires* 1994;19:206-9.
- 29 Przybylowski J, Podolecki A, Laks L et al. [Health status of workers in polyvinyl chloride processing plants. I. Evaluation of occupational exposure. Subjective and

Formatted: French (France)

Formatted: French (France)

Formatted: French (France)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

capillaroscopy studies. Conduction velocity in the motor nerves]. *Med Pr* 1983;34:385-96.

Formatted: French (France)

- 30 Jiao J, Feng NN, Li Y et al. Estimation of a Safe Level for Occupational Exposure to Vinyl Chloride Using a Benchmark Dose Method in Central China. *J Occup Health* 2012.
- 31 Carpentier PH. New techniques for clinical assessment of the peripheral microcirculation. *Drugs* 1999;59 Spec No:17-22.
- 32 Laplanche A, Clavel F, Contassot JC, Lanouziere C. Exposure to vinyl chloride monomer: report on a cohort study. *Br J Ind Med* 1987;44:711-5.
- 33 Prasad A, Dunnill GS, Mortimer PS, MacGregor GA. Capillary rarefaction in the forearm skin in essential hypertension. *J Hypertens* 1995;13:265-8.
- 34 Bonacci E, Santacroce N, D'Amico N, Mattace R. Nail-fold capillaroscopy in the study of microcirculation in elderly hypertensive patients. *Arch Gerontol Geriatr* 1996;22 Suppl 1:79-83.
- 35 Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Structural skin capillary rarefaction in essential hypertension. *Hypertension* 1999;33:998-1001.
- 36 Lehr HA. Microcirculatory dysfunction induced by cigarette smoking. *Microcirculation* 2000;7:367-84.
- 37 Lova RM, Miniati B, Macchi C et al. Morphologic changes in the microcirculation induced by chronic smoking habit: a videocapillaroscopic study on the human labial mucosa. *Am Heart J* 2002;143:658.
- 38 Betta A, Tommasini M, Bovenzi M, Barbone F, Versini W, Romeo L. [Scleroderma and occupational factors: a case-control study and analysis of literature]. *Medicina del Lavoro* 1994;85:496-506.
- 39 Ostlere LS, Harris D, Buckley C, Black C, Rustin MH. Atypical systemic sclerosis following exposure to vinyl chloride monomer. A case report and review of the cutaneous aspects of vinyl chloride disease. *Clinical and Experimental Dermatology* 1992;17:208-10.
- 40 Block JA, Sequeira W. Raynaud's phenomenon. *Lancet* 2001;357:2042-8.
- 41 Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. *Nat Rev Rheumatol* 2012;8:469-79.
- 42 Koischwitz D, Marsteller HJ, Lackner K, Brecht G, Brecht T. [Changes in the arteries in the hand and fingers due to vinyl chloride exposure (author's transl)]. *Rofo* 1980;132:62-8.
- 43 Duteil F, Kelly C, Biat I et al. [Relation between the level of knowledge and the rate of vaccination against the flu virus among the staff of the Clermont-Ferrand University hospital]. *Med Mal Infect* 2008;38:586-94.
- 44 Chiew M, Weber MF, Egger S, Sitas F. A cross-sectional exploration of smoking status and social interaction in a large population-based Australian cohort. *Social Science and Medicine* 2012;75:77-86.
- 45 Penforis A, San-Galli F, Cimino L, Huet D. Current insulin therapy in patients with type 2 diabetes: results of the ADHOC survey in France. *Diabetes and Metabolism* 2011;37:440-5.
- 46 Heinavaara S, Tokola K, Kurttio P, Auvinen A. Validation of exposure assessment and assessment of recruitment methods for a prospective cohort study of mobile phone users (COSMOS) in Finland: a pilot study. *Environ Health* 2011;10:14.
- 47 Eriksen L, Gronbaek M, Helge JW, Tolstrup JS, Curtis T. The Danish Health Examination Survey 2007-2008 (DANHES 2007-2008). *Scand J Public Health* 2011;39:203-11.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only





Table 1 Characteristics of participants, exposure to VCM and capillaroscopic outcomes.


	Retired from exposure to VCM (n=21)	Controls (n=40)	p- value
Age – years	74.4±2.9	76.3±3.2	NS
type of occupation: blue collar workers – “manual”	100%	100%	NS
Exposure to VCM:			
direct contact with VCM	100%	0	<.001
exposure time – years	29.8±1.9	0	<.001
time after exposure – years	15.9±2.4	-	-
Main capillaroscopic outcomes:			
1. density			
mean density – mm	8.6±0.4	8.8±0.3	NS
decreased capillary density <10/mm – n (%)	9 (43)	16 (46)	NS
avascular zone <7/mm – n(%)	0	0	NS
2. length			
mean length – μm	291±14 [†]	254±9 [†]	.020
augmented capillary length >300 μm – n(%)	7 (33)	0	<.001
3. diameter			
mean diameter of capillaries – μm	28.9±0.9 [†]	25.7±0.6 [†]	.006
enlarged capillaries >2530 μm – n(%)	4 (19)	0	<.001
megacapillary >50 μm – n(%)	0	0	NS
4. dystrophy			
capillary branching >15% – n(%)	6 (29)	0	<.001
5. hemorrhage – n(%)			
0	0	0	NS
Symptoms of Raynaud:			
n(%) with Raynaud	4 (19)	0	.007
Participants with medications which could induce Raynaud – n(%)	2 (9)	4 (11)	NS
Other causes of Raynaud	0	0	NS
Comorbidities			
Respiratory diseases	2 (9)	6 (17)	NS
Cardiovascular diseases (except high blood pressure)	4 (19)	5 (14)	NS
Myocardial infraction	3 (14)	3(9)	NS
Routine medications – n(%) of patients treated for:			
Blood pressure	7 (33)	13 (37)	NS
Lipid lowering	4 (19)	6 (17)	NS
Smoking – n(%)	9 (43)	18 (51)	NS

Figure 1 Participant flow chart.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2 Normal capillaroscopy on a control participant (A) and capillaroscopy with dystrophia >15% in a retired worker exposed to VCM for 37 years, with no treatment and no comorbidity, non smoking (B).





The long-term effects of occupational exposure to vinyl chloride monomer on microcirculation: a cross-sectional study 15 years after retirement

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002785.R2
Article Type:	Research
Date Submitted by the Author:	23-Apr-2013
Complete List of Authors:	Lopez, Vincent; CHU G. Montpied, Chamoux, Alain; CHU G. Montpied, Tempier, Marion; CHU G. Montpied, Thiel, Helene; CHU G. Montpied, Ughetto, Sylvie; CHU G. Montpied, Trousselard, Marion; IRBA, Naughton, Geraldine; Australian Catholic University, School of Exercise Science Dutheil, Frederic; CHU G. Montpied,
Primary Subject Heading:	Occupational and environmental medicine
Secondary Subject Heading:	Public health
Keywords:	OCCUPATIONAL & INDUSTRIAL MEDICINE, CHEMICAL PATHOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

only

1
2
3 **The long-term effects of occupational exposure to vinyl chloride monomer**
4
5 **on microcirculation: a cross-sectional study 15 years after retirement**
6
7
8
9

10
11
12
13 Vincent Lopez ¹, Alain Chamoux ¹, Marion Tempier ², H el ene Thiel ³, Sylvie Ughetto ⁴,
14
15 Marion Trousselard ⁵, Geraldine Naughton ⁶, Fr ed eric Dutheil ^{1,6,7,*}
16
17

18
19
20 ¹ Occupational Medicine, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand,
21
22 France

23
24 ² Radiopharmacy, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand, France

25
26 ³ Vascular Medicine, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand,
27
28 France

29
30
31 ⁴ Department of Medical Information - Clinical research and innovation direction, University
32
33 Hospital CHU G. Montpied, 63000 Clermont-Ferrand, France

34
35 ⁵ Neurophysiology of emotions, ENOP department, CRSSA/IRBA, 38702 La Tronche,
36
37 France

38
39
40 ⁶ School of Exercise Science, Australian Catholic University, Locked Bag 4115 Fitzroy MDC
41
42 VIC 3065, Australia

43
44 ⁷ Laboratory of Metabolic Adaptations to Exercise in Physiological and Pathological
45
46 conditions (AME2P, EA3533), 63000 Clermont-Ferrand, France

47
48
49
50
51 ***Correspondance to** Fr ed eric Dutheil, Occupational Medicine, University Hospital CHU G.
52
53 Montpied, 63000 Clermont-Ferrand, France Tel: +33 6 88 22 48 48. Fax: +33 4 73 27 46 49.
54
55 fred_dutheil@yahoo.fr.
56
57
58
59
60

1
2
3 Running Title: Capillaroscopy post-exposure to VCM
4

5 Words count for introduction methods results discussion conclusion: 2402
6

7 Number of tables: 1
8

9 Number of figures: 2
10

11 Words count for abstract: 262
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Objectives: To assess residual long-term microcirculation abnormalities by capillaroscopy, 15 years after retiring from occupational exposure to vinyl chloride monomer (VCM).

Design: Cross-sectional study.

Setting: Allier, one of the major area of PVC production in France.

Participants: We screened 761 (97% males) retired workers exposed to chemical toxics. Exposure to chemical other than VCM excluded potential participants.

Primary and secondary outcomes measures: These participants underwent a medical examination including a capillaroscopy, symptoms of Raynaud, and comorbidities, as well as a survey to determine exposure time, direct or indirect contact, type of occupation, smoking status and time after exposure. A double blind analysis of capillaroscopic images was done. A control group was matched in age, sex, type of occupation.

Results: 179/761 retired workers were only exposed to VCM at their work, with 21 meeting the inclusion criteria and included. Exposure time was 29.8 ± 1.9 years and time after exposure was 15.9 ± 2.4 years. Retired workers previously exposed to VCM had significantly higher capillaroscopic modifications than 35 controls: enlarged capillaries (19% vs. 0%, $p < .001$), dystrophy (28.6% vs. 0%, $p = .0012$), and augmented length (33% vs. 0%, $p < .001$). Time exposure was linked ($p < .0001$) with enlarged capillaries ($R^2 = .63$), dystrophy ($R^2 = .51$), and capillary length ($R^2 = .36$). They also had higher symptoms of Raynaud (19% vs. 0%, $p = .007$) without correlation with capillaroscopic modifications.

Conclusion: Although VCM exposure was already known to affect microcirculation, our study demonstrates residual long term abnormalities following an average of 15 years retirement, with a time-related exposure response. Symptoms of Raynaud, although statistically associated with exposure was not related to capillaroscopic modifications; its origin remains to be determined.

1
2
3 **Keywords** Exposition, Vinyl chloride monomer, Capillaroscopy, Raynaud
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ARTICLE SUMMARY

Article focus

- Vinyl chloride monomer exposure induces microcirculation abnormalities, which can be diagnosed by capillaroscopy.
- Residual long-term abnormalities following retirement required investigation.

Key messages

- Our results demonstrated residual long-term abnormalities following an average of 15 years retirement, with a time-related exposure response.
- Symptoms of Raynaud, although statistically associated with exposure, was not related to capillaroscopic modifications; its origin remains to be determined.

Strengths and limitations of this study

- The strong points is that this study had a rigorous selection criteria of exclusively VCM exposed participants avoided confounding factor and the focus on retired workers at least 15 years after the end of occupational VCM exposure.
- The main limitation is that pathophysiology of Raynaud after VCM exposure remains unclear.

INTRODUCTION

Vinyl chloride monomer (VCM) is primarily used in the manufacture of plastics and also serves as a raw material in organic synthesis. VCM is an aliphatic hydrocarbon also known as chloroethene. Its polymerization lead to a synthetic resin called polyvinyl chloride, commonly abbreviated PVC. PVC, is the third-most widely produced plastic, after polyethylene and polypropylene.¹ PVC can be made softer and more flexible by the addition of phthalates, and may also replace rubber. Thus, PVC is widely used including: pipes and water distribution, a substitute for painted wood (e.g. window frames, sills, flooring), electrical cable insulation, inflatable products, waterproof clothing (e.g. coats, skiing equipment, shoes), healthcare products (e.g. containers, tubing, catheters), food packaging, dental appliances and vinyl records.¹

Harmless in its polymeric form, workers handling the finished PVC product are perfectly safe. In contrast, the at-risk phase lies in the manual descaling of autoclaves used for the polymerization where workers can contact it during its monomer state.² The chronic intoxication by gaseous monomer VCM is linked to several symptoms such as:³ asthenia and dizziness,³ Raynaud's syndrome,^{4 5} digestive ulcers with nausea and anorexia,³ systemic symptoms of arthralgia and myalgia³, trophic cutaneous symptoms and sclerosis. It has also been suspected in the onset of acroosteolysis^{4 6 7} and hepatocellular carcinoma.^{8 9} More generally, VCM exposure involves chromosomal aberrations and increased carcinogenic risk.¹⁰ Even if VCM related diseases may have a genetic bases, they are also linked to prolonged occupational VCM exposure.^{5 11}

Scleroderma-like microvascular abnormalities have been also described on exposed workers.¹²⁻¹⁴ The most common and non-invasive means of investigating these abnormalities is capillaroscopy. Widespread identification of individuals most at risk could enable early detection and management strategy.¹⁵ The residual effects of VCM on microcirculation have

1
2
3 been shown only once on 15 workers who had ceased their VCM exposure six months prior to
4 testing.¹³ However, residual long-term abnormalities following retirement are unknown. Our
5
6 hypothesis was higher capillaroscopic abnormalities in the VCM exposed group than in the
7
8 control group.
9

10
11 Therefore, the aim of our cross-sectional study was to investigate residual long-term
12
13 capillaroscopic abnormalities following retirement, after 15 years without VCM exposure.
14
15

16 17 18 19 20 21 **METHODS**

22 23 **Participants**

24
25 We enrolled male retired workers exposed to VCM in PVC production. They provided written
26
27 informed consent. The study was approved by the human ethics committees from Clermont-
28
29 Ferrand university hospital, France. To be eligible, participants had to be: male (due to male
30
31 dominance in this workforce), retired, aged over 60 years, with at least a 5-year occupational
32
33 exposure to VCM, a time after VCM exposure of at least 5 years, and no exposure to
34
35 chemicals other than VCM. Moreover, participants with diabetes mellitus were also excluded
36
37 as it may interfere with microcirculation,¹⁶⁻²¹ as well as individuals declaring the use or
38
39 previous use of treatments which may alter microcirculation.
40
41

42
43 Participants responded to a survey to determine exposure time, direct or indirect contact, type
44
45 of occupation, time after exposure and smoking history. They underwent a medical
46
47 examination including a capillaroscopy, symptoms of Raynaud, and comorbidities such as
48
49 pathologies that may interfere with microcirculation (arterial hypertension, dyslipidemia) or
50
51 pathologies potentially linked with VCM exposure (cardiovascular or respiratory diseases).²²
52
53
54
55
56
57
58
59
60

1
2
3 A control group was matched in age, sex, type of occupation. They were recruited via
4 advertisements. Selection criteria for this group also included no occupational or leisure
5 chemical exposure, and no diabetes mellitus.¹⁶⁻²¹
6
7
8
9

10 11 12 **Capillaroscopy**

13 A nailfold capillaroscopy was performed on all fingers of each patient, excluding thumbs.²³
14 The nailfold capillaroscopies of the fingers were captured in images and electronically stored.
15 The same investigator conducted all the capillaroscopies. A double blind analysis of
16 capillaroscopic images was completed on deidentified data.
17
18
19
20
21
22

23 The outcomes were the five following classical criteria used in capillaroscopy: density,
24 length, diameter, dystrophy and hemorrhage. Criteria for abnormalities were defined as:
25 decreased capillary density <10/mm (avascular zone <7/mm),²⁴ augmented capillary length
26 >300µm,^{24 25} increased capillary diameter >25µm²⁵ (megacapillary >50µm)^{26 27}, and
27 dystrophy was associated with capillary branching >15%.²⁸ Hemorrhage is defined as the
28 microvascular extravasation of the red blood cells linked to the damage of the vessel wall.²⁷
29
30
31
32
33
34
35
36
37
38

39 **Statistics**

40 Data are presented as mean percentage change and standard deviation (SD).
41 The main judgment criterion for abnormal microcirculation was the presence of at least one
42 abnormality in capillaroscopy. Under the assumption of similar proportions of abnormalities
43 as that reported during a VCM exposure,¹²⁻¹⁴ our sample calculation indicated that we would
44 need 27 participants in each of the exposed and non-exposed groups to find a change in
45 probability of 35% (i.e., 40% in exposed versus 5% in non-exposed) for a power of 80% and a
46 two-sided alpha of 5%. When we considered an exposed to non-exposed sample ratio of 1:2,
47 19 and 38 participants, respectively were needed in the exposed and non-exposed groups.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Under the assumption of 0% prevalence in the non-exposed group, sample sizes of 13
4 exposed and 26 non-exposed were required.

5
6
7 Statistical analyses were performed with SPSS software, v19. Correlations were used for
8 inter-observer reliability. The Gaussian distribution for each parameter was assessed by a
9 Shapiro-Wilk test. Comparisons between groups (exposed vs. control) were made through the
10 usual tests: Chi2 test for categorical variables (or Fisher's exact test where appropriate) and
11 Student's t test for quantitative variables (or Kruskal-Wallis if assumptions of normal
12 distribution were violated). Significance was accepted for a p-value < 5%. The links between
13 continuous variables were analyzed using linear regression. The links between binary and
14 continuous variables were analyzed with logistic regression (Nagelkerke R Square).
15
16 Multivariate models were used to predict the relationship between capillary parameters and
17 other parameters such as exposure time and time after exposure.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **RESULTS**

37 **Participants**

38
39 We screened 761 (97% males) retired workers exposed to chemical toxics from two leading
40 enterprises involved in PVC production (n=435 and n=91), as well as participants from many
41 subcontracting companies (n=235), also known for VCM exposure. The strict selection
42 criteria of exposure only to VCM reduced the sample size to 21 (figure 1).
43
44
45
46
47
48

49 Thirty five age-matched controls were also recruited without occupational or leisure time
50 exposure to chemical toxics.
51
52
53
54
55

56 **Main capillaroscopic outcomes**

1
2
3 There was no missing data. Inter-rater reliability was confirmed with correlations exceeding
4 0.70 for each parameter. The mean of the values of the 2 investigators is presented in table 1.
5
6 Concerning the qualitative data, when a disagreement occurred, the two observers analyzed
7 again together and requested the opinion of a third expert. The disagreement occurred only for
8
9 2 decreased capillary density <10/mm, and 1 capillary branching >15%.

10
11 Compared with controls, retired workers previously exposed to VCM had higher
12 capillaroscopic abnormalities: enlarged capillaries (0% vs. 19%, $p<.001$), dystrophy (0% vs.
13 28.6%, $p=.0012$) (figure 2), and augmented length (0% vs. 33%, $p<.001$). The mean length
14 was 15% higher in the exposed group than in controls ($p=.020$), as well as a 12% greater
15 diameter of capillaries ($p=.006$) (table 1).
16
17
18
19
20
21
22
23
24
25
26

27 **Exposure**

28
29 Exposure time was 29.8 ± 1.9 years and time after exposure was 15.9 ± 2.4 years. Time of
30 exposure to VCM was strongly linked with enlarged capillaries (Nagelkerke R Square
31 approximation of 63%, $p<.0001$), with dystrophy (Nagelkerke R Square approximation of
32 51%, $p<.0001$), and modestly linked with capillary length expressed as binary data
33 (Nagelkerke R Square approximation of 36%, $p<.0001$) or as quantitative data ($R^2 = 8\%$;
34 $p=.031$) (table 1). Age was not associated with capillaroscopic abnormalities. No multivariate
35 models improved results from simple regressions.
36
37
38
39
40
41
42
43
44
45
46

47 **Symptoms of Raynaud**

48
49 VCM exposed group also had more symptoms of Raynaud (19% vs. 0%, $p=.007$) independent
50 of capillaroscopic modifications (table 1).
51
52
53
54
55
56
57
58
59
60

Comorbidities and smoking

Neither respiratory nor cardiovascular diseases were associated with VCM exposure. However, we combined both groups to explore potential associations between capillaroscopic parameters and high blood pressure, dyslipidemia, and smoking. Capillary length in participants medicated for arterial hypertension (n=20/61) did not differ from participants without hypertension. Participants treated with lipid lowering drugs with dyslipidemia (n=10/61) also showed a trend for a higher capillary length than participants without dyslipidemia (p=.079). Finally, there were no capillaroscopic difference between smokers and non smokers. However, smokers who had been exposed to VCM tended to have a higher capillary length than non smokers (p=.073).

DISCUSSION

Principal findings of the study

Changes in microcirculation persist for at least 15 years following occupational VCM exposure, with a time-related exposure response. Symptoms of Raynaud, although statistically associated with exposure, was not related to pathological capillaroscopic changes.

What the study adds

The microcirculation changes following VCM exposure has been previously shown on 15 workers who ceased their occupational exposure six months prior to testing.¹³ Our study supports these results over a longer period following VCM exposure – 15 years.

The dose responsiveness of VCM exposure and compromised capillarisation is generally,¹³ but not always,¹² reported. Although daily VCM doses may have been more informative, the

1
2
3 current study was restricted to years of exposure. Thus, we are limited to describing
4
5 associations with an exposure time – response rather than a dose-response. Years of exposure
6
7 is an easy question for physicians to ask of workers during risk assessment protocols.
8

9
10 The absence of changes in microcirculation on less exposed workers²⁹ resulted in a suggestion
11
12 that a threshold of exposure exists. This finding is supported by previous studies showing that
13
14 long-term exposure (>8 years) induced greater chromosomal aberrations.^{10 30} Further, not all
15
16 workers exposed to VCM develop microvascular abnormalities, suggestive of an underlying
17
18 genetic susceptibility (polymorphism of glutathione S-transferase).^{5 11} A finding that female
19
20 VCM-exposed workers were more susceptible than males to the risk of increased
21
22 chromosome damage also reinforced genetic susceptibility theory.³⁰
23
24
25
26

27 **Comparison with other studies**

28
29 After 50 years of age, minor dystrophies could alter readability and interpretation of
30
31 capillaroscopic analyses.³¹ Nevertheless, we controlled this parameter by matching the
32
33 exposed group and the controls on age and we conducted a double-blind analysis by two
34
35 experienced readers. Moreover, capillaroscopic abnormalities among workers exposed to
36
37 VCM in the present study were not influenced by age.¹³
38
39

40
41 VCM has been suspected of causing respiratory and circulatory diseases.³² However, similar
42
43 frequencies of these diseases in both groups do not support this hypothesis.
44

45
46 Diabetes mellitus,¹⁶⁻²¹ high blood pressure,^{18 33-35} dyslipidemia,³⁴ or some
47
48 comorbidities/medications²² could interfere with microcirculation. In line with previous
49
50 studies, we showed a diminished capillary length in participants treated for arterial
51
52 hypertension,^{18 33-35} and a trend for participants treated with lipid lowering drugs.³⁴ Diabetes
53
54 mellitus was an exclusion criterion and thus, could not interfere with our results. Perhaps due
55
56 to low numbers of participants, our results failed to support previous findings of compromised
57
58
59
60

1
2
3 microcirculation in people with high blood pressure. The trend for increased capillary length
4
5 observed in our participants with dyslipidemia could be a response to increased peripheral
6
7 vascular resistance, in order to maintain their function of metabolic exchange.³⁵ Similarly,
8
9 smoking could induce a decrease in tissue perfusion,³⁶ and dystrophia.³⁷ We did not observe
10
11 differences between smokers and non-smokers, with the exception of a trend for abnormal
12
13 microcirculation among smokers exposed to VCM. The potential of a synergistic effect of
14
15 tobacco and VCM-exposure warrants further investigations. It should be noted that VCM
16
17 exposure in the current study was more strongly associated with compromised
18
19 microcirculation than high blood pressure, dyslipidemia and smoking.
20
21

22
23 Previous research into the links between systemic sclerosis and VCM exposure is limited by
24
25 single case design³⁸ and somewhat dated analyses of a population exposed to solvents.³⁹ The
26
27 broader use of term such as solvents is less specific than the VCM exposure carefully isolated
28
29 for investigation in the present study.
30

31
32 A higher prevalence of symptoms of Raynaud has been established in workers with VCM
33
34 exposure,³² up to one third of the exposed workers.¹³ The comparison between studies with
35
36 different selection criteria and different sample sizes is difficult. There is also the possibility
37
38 of selection bias in non randomized recruitment. Within these limitations, our results support
39
40 previous data, and extend knowledge by demonstrating the prevalence of symptoms of
41
42 Raynaud remained higher at least 15 years following VCM exposure. Furthermore, in the
43
44 current study, all the participants who suffered from symptoms of Raynaud had never taken
45
46 medications or suffered from other diseases conducive to Raynaud.
47
48
49
50

51 **Unanswered questions**

52
53 Although symptoms of Raynaud are statistically associated with VCM exposure, we could not
54
55 report a link with capillaroscopic modifications. The pathophysiology of Raynaud's
56
57
58
59
60

1
2
3 phenomenon remains unknown. There seems to be primary or secondary vascular failure
4 influenced by a hereditary factor.⁴⁰ Decreased perfusion pressure could be secondary to
5 systemic hypotension or be caused by proximal arterial occlusion, influenced by many
6 factors; both vascular and intra vascular, neural, environmental or hereditary.⁴¹ Angiography
7 of the hands of patients exposed to VCM showed occlusions, stenosis and narrowing of distal
8 arteries with the development of collateral circulation.⁴² Lack of statistical power in our study
9 could contribute to the lack of relationship between capillaroscopic changes and symptoms of
10 Raynaud.
11
12
13
14
15
16
17
18
19

20 21 22 23 **Strengths and limitations of study**

24 This study presents some major strengths: a rigorous selection criteria of exclusively VCM
25 exposed participants avoided confounding factors, well-matched controls, a double blind
26 analyses, sufficient number of participants to detect the capillaroscopic differences between
27 groups, the focus on retired workers at least 15 years after the end of occupational VCM
28 exposure. The attendance rate of 30% (53 of 179 individuals exclusively exposed to VCM at
29 work agreed to participate in our study) seems very high compared with other studies⁴³⁻⁴⁷
30 taking into account their age (75 years), distance from the location of the medical examination
31 (averaging approximately 80 km), and that no financial compensation was offered.
32
33
34
35
36
37
38
39
40
41

42 There are limitations to this study. The cross-sectional design has limitations; however, proof
43 of concept was important and achieved (with a possibility of longitudinal follow-up).
44 Differences in some but not all capillary outcomes may be explained by a lack of statistical
45 power. The results are insufficient to propose guidelines for all workers exposed to VCM.
46 More accurate quantifiable measures of VCM exposure are not available; however, for the
47 purpose of this study we used industry established lists of exposure legally required in France.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 may lie in the fact that most of the retired workers exposed to VCM were from the same
4
5 enterprise; thus, potentially more at-risk manufacturing processes remained undetected.
6
7 Gender specificity may warrant future studies.
8
9

10 11 12 13 14 15 **CONCLUSION**

16
17 Although VCM exposure was already known to affect microcirculation, our study
18
19 demonstrated the potential for residual long-term abnormalities following an average of 15
20
21 years retirement, with a time exposure – response. Symptoms of Raynaud, although
22
23 statistically associated with exposure were not associated with capillaroscopic modifications;
24
25 its origin remains to be determined. Future research could focus on other chemical products
26
27 which have a similar structure than VCM and more extensive research on type of occupations
28
29 at-risk of VCM exposure.
30
31
32
33
34
35
36
37

38 **Role of the Funding Source**

39
40 The Occupational Medicine department of CHU G. Montpied, Clermont-Ferrand, France
41
42 funded this study. No other funding source had a role in the design, conduct, or reporting of
43
44 the study.
45
46
47

48 **Contributors**

49
50 VL has participated as a MD student and principal investigator. FD and AC obtained research
51
52 funding and generated the intellectual development of the study. FD knew potential exposed
53
54 workers to VCM. VL, FD, AC and SH contributed to the conception of the protocol. VL, FD
55
56 and SH made data analysis. VL, FD, MT contributed to manuscript drafting. VL recruited all
57
58
59
60

1
2
3 participants and performed all capillaroscopies. VL and MT completed the double blind
4
5 analyses of capillaroscopy. FD, AC, VL, GN and MT revised the manuscript. All authors read
6
7 and approved the final manuscript.
8
9

10 11 **Competing Interests**

12
13
14 None
15
16

17 18 **Data sharing**

19
20 No additional data available.
21
22

23 24 **Acknowledgments**

25
26 Our thanks to Dr George Mnatzaganian for help with statistics (Faculty of Health Sciences,
27
28 Australian Catholic University, Fitzroy, Victoria, Australia, email:
29
30 George.Mnatzaganian@acu.edu.au). We also want to acknowledge the “Association of the
31
32 sick from chemicals” (Association des Malades de la Chimie), 15 Av Albert Poncet 03410
33
34 Domerat, France, which helped us recruit the retired workers from VCM exposure.
35
36
37
38
39

40 41 **REFERENCES**

- 42
43
44
45 1 Allsopp M, Giovanni G. Poly(Vinyl Chloride) *Ullmann's Encyclopedia of Industrial*
46 *Chemistry* 2000.
47 2 Fontana L, Baietto M, Becker F, et al. [Clinical and capillaroscopic study of
48 Raynaud's phenomenon in retired patients previously exposed to vinyl chloride
49 monomer]. *J Mal Vasc* 1995;20:268-73.
50 3 Veltman G, Lange CE, Juhe S, Stein G, Bachner U. Clinical manifestations and course
51 of vinyl chloride disease. *Ann N Y Acad Sci* 1975;246:6-17.
52 4 Harris DK, Adams WG. Acro-osteolysis occurring in men engaged in the
53 polymerization of vinyl chloride. *Br Med J* 1967;3:712-4.
54 5 Fontana L, Marion MJ, Ughetto S, et al. Glutathione S-transferase M1 and GST T1
55 genetic polymorphisms and Raynaud's phenomenon in French vinyl chloride
56 monomer-exposed workers. *J Hum Genet* 2006;51:879-86.
57
58
59
60

- 1
2
3 6 Preston BJ, Jones KL, Grainger RG. Clinical aspects of vinyl chloride disease: acro-
4 osteolysis. *Proc R Soc Med* 1976;69:284-6.
5 7 Wilson RH, McCormick WE, Tatum CF, Creech JL. Occupational acroosteolysis.
6 Report of 31 cases. *JAMA* 1967;201:577-81.
7 8 Dragani TA, Zocchetti C. Occupational exposure to vinyl chloride and risk of
8 hepatocellular carcinoma. *Cancer Causes Control* 2008;19:1193-200.
9 9 Mundt KA, Dell LD, Austin RP, et al. Historical cohort study of 10 109 men in the
10 North American vinyl chloride industry, 1942-72: update of cancer mortality to 31
11 December 1995. *Occup Environ Med* 2000;57:774-81.
12 13 Kumar AK, Balachandar V, Arun M et al. A Comprehensive Analysis of Plausible
14 Genotoxic Covariates Among Workers of a Polyvinyl Chloride Plant Exposed to
15 Vinyl Chloride Monomer. *Arch Environ Contam Toxicol* 2012.
16 17 Ji F, Zhu S, Sun P, Wang W. [Relationship between genetic polymorphisms of phase I
18 and phase II metabolizing enzymes and DNA damage of workers exposed to vinyl
19 chloride monomer]. *Wei Sheng Yan Jiu* 2009;38:7-11.
20 21 Langauer-Lewowicka H. Nailfolds capillary abnormalities in polyvinyl chloride
22 production workers. *Int Arch Occup Environ Health* 1983;51:337-40.
23 24 Maricq HR, Darke CS, Archibald RM, et al. In vivo observations of skin capillaries in
25 workers exposed to vinyl chloride. An English-American comparison. *Br J Ind Med*
26 1978;35:1-7.
27 28 Maricq HR, Johnson MN, Whetstone CL, et al. Capillary abnormalities in polyvinyl
29 chloride production workers. Examination by in vivo microscopy. *JAMA*
30 1976;236:1368-71.
31 32 Kowal-Bielecka O, Bielecki M, Kowal K. Recent advances in the diagnosis and
33 treatment of systemic sclerosis. *Polskie Archiwum Medycyny Wewnetrznej*
34 2013;123:51-8.
35 36 Pazos-Moura CC, Moura EG, Bouskela E, et al. Nailfold capillaroscopy in non-insulin
37 dependent diabetes mellitus: blood flow velocity during rest and post-occlusive
38 reactive hyperaemia. *Clin Physiol* 1990;10:451-61.
39 40 Iabichella ML, Mariotti R, Nuti M, et al. [Site specificity of biomicroscopic pattern in
41 diabetic patients]. *Minerva Cardioangiol* 1999;47:619-21.
42 43 Lambova SN, Muller-Ladner U. The specificity of capillaroscopic pattern in
44 connective autoimmune diseases. A comparison with microvascular changes in
45 diseases of social importance: arterial hypertension and diabetes mellitus. *Mod*
46 *Rheumatol* 2009;19:600-5.
47 48 Vayssairat M, Le Devehat C. [Critical analysis of vascular explorations in diabetic
49 complications]. *J Mal Vasc* 2001;26:122-5.
50 51 Meyer MF, Pfohl M, Schatz H. [Assessment of diabetic alterations of microcirculation
52 by means of capillaroscopy and laser-Doppler anemometry]. *Med Klin (Munich)*
53 2001;96:71-7.
54 55 Chang CH, Tsai RK, Wu WC, et al. Use of dynamic capillaroscopy for studying
56 cutaneous microcirculation in patients with diabetes mellitus. *Microvasc Res*
57 1997;53:121-7.
58 59 Gallucci F, Russo R, Buono R, et al. Indications and results of videocapillaroscopy in
60 clinical practice. *Adv Med Sci* 2008;53:149-57.
23 Hern S, Mortimer PS. Visualization of dermal blood vessels--capillaroscopy. *Clin Exp Dermatol* 1999;24:473-8.
24 Ingegnoli F, Gualtierotti R, Lubatti C et al. Feasibility of different capillaroscopic measures for identifying nailfold microvascular alterations. *Seminars in Arthritis and Rheumatism* 2009;38:289-95.

- 1
2
3 25 Kabasakal Y, Elvins DM, Ring EF, et al. Quantitative nailfold capillaroscopy findings
4 in a population with connective tissue disease and in normal healthy controls. *Ann*
5 *Rheum Dis* 1996;55:507-12.
- 6 26 Bhakuni DS, Vasdev V, Garg MK, et al. Nailfold capillaroscopy by digital microscope
7 in an Indian population with systemic sclerosis. *Int J Rheum Dis* 2012;15:95-101.
- 8 27 Cutolo M, Pizzorni C, Secchi ME, et al. Capillaroscopy. *Best Pract Res Clin*
9 *Rheumatol* 2008;22:1093-108.
- 10 28 Jouanny P, Schmidt C, Feldmann L, et al. [Focus on a quick reading of nailfold
11 capillaroscopy]. *Journal des Maladies Vasculaires* 1994;19:206-9.
- 12 29 Przybylowski J, Podolecki A, Laks L et al. [Health status of workers in polyvinyl
13 chloride processing plants. I. Evaluation of occupational exposure. Subjective and
14 capillaroscopy studies. Conduction velocity in the motor nerves]. *Med Pr*
15 1983;34:385-96.
- 16 30 Jiao J, Feng NN, Li Y et al. Estimation of a Safe Level for Occupational Exposure to
17 Vinyl Chloride Using a Benchmark Dose Method in Central China. *J Occup Health*
18 2012.
- 19 31 Carpentier PH. New techniques for clinical assessment of the peripheral
20 microcirculation. *Drugs* 1999;59 Spec No:17-22.
- 21 32 Laplanche A, Clavel F, Contassot JC, et al. Exposure to vinyl chloride monomer:
22 report on a cohort study. *Br J Ind Med* 1987;44:711-5.
- 23 33 Prasad A, Dunnill GS, Mortimer PS, et al. Capillary rarefaction in the forearm skin in
24 essential hypertension. *J Hypertens* 1995;13:265-8.
- 25 34 Bonacci E, Santacroce N, D'Amico N, et al. Nail-fold capillaroscopy in the study of
26 microcirculation in elderly hypertensive patients. *Arch Gerontol Geriatr* 1996;22
27 Suppl 1:79-83.
- 28 35 Antonios TF, Singer DR, Markandu ND, et al. Structural skin capillary rarefaction in
29 essential hypertension. *Hypertension* 1999;33:998-1001.
- 30 36 Lehr HA. Microcirculatory dysfunction induced by cigarette smoking.
31 *Microcirculation* 2000;7:367-84.
- 32 37 Lova RM, Miniati B, Macchi C et al. Morphologic changes in the microcirculation
33 induced by chronic smoking habit: a videocapillaroscopic study on the human labial
34 mucosa. *Am Heart J* 2002;143:658.
- 35 38 Betta A, Tommasini M, Bovenzi M, et al. [Scleroderma and occupational factors: a
36 case-control study and analysis of literature]. *Medicina del Lavoro* 1994;85:496-506.
- 37 39 Ostlere LS, Harris D, Buckley C, et al. Atypical systemic sclerosis following exposure
38 to vinyl chloride monomer. A case report and review of the cutaneous aspects of vinyl
39 chloride disease. *Clinical and Experimental Dermatology* 1992;17:208-10.
- 40 40 Block JA, Sequeira W. Raynaud's phenomenon. *Lancet* 2001;357:2042-8.
- 41 41 Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. *Nat*
42 *Rev Rheumatol* 2012;8:469-79.
- 43 42 Koischwitz D, Marsteller HJ, Lackner K, et al. [Changes in the arteries in the hand and
44 fingers due to vinyl chloride exposure (author's transl)]. *Rofo* 1980;132:62-8.
- 45 43 Dutheil F, Kelly C, Biat I et al. [Relation between the level of knowledge and the rate
46 of vaccination against the flu virus among the staff of the Clermont-Ferrand
47 University hospital]. *Med Mal Infect* 2008;38:586-94.
- 48 44 Chiew M, Weber MF, Egger S, et al. A cross-sectional exploration of smoking status
49 and social interaction in a large population-based Australian cohort. *Social Science*
50 *and Medicine* 2012;75:77-86.
- 51
52
53
54
55
56
57
58
59
60

- 1
2
3 45 Penformis A, San-Galli F, Cimino L, et al. Current insulin therapy in patients with type
4 2 diabetes: results of the ADHOC survey in France. *Diabetes and Metabolism*
5 2011;37:440-5.
6 46 Heinavaara S, Tokola K, Kurttio P, et al. Validation of exposure assessment and
7 assessment of recruitment methods for a prospective cohort study of mobile phone
8 users (COSMOS) in Finland: a pilot study. *Environ Health* 2011;10:14.
9 47 Eriksen L, Gronbaek M, Helge JW, et al. The Danish Health Examination Survey
10 2007-2008 (DANHES 2007-2008). *Scand J Public Health* 2011;39:203-11.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1 Characteristics of participants, exposure to VCM and capillaroscopic outcomes.

	Retired from exposure to VCM (n=21)	Controls (n=40)	p- value
Age – years	74.4±2.9	76.3±3.2	NS
type of occupation: blue collar workers – “manual”	100%	100%	NS
Exposure to VCM:			
direct contact with VCM	100%	0	<.001
exposure time – years	29.8±1.9	0	<.001
time after exposure – years	15.9±2.4	-	-
Main capillaroscopic outcomes:			
1. density			
mean density – mm	8.6±0.4	8.8±0.3	NS
decreased capillary density <10/mm – n (%)	9 (43)	16 (46)	NS
avascular zone <7/mm – n(%)	0	0	NS
2. length			
mean length – µm	291±14	254±9	.020
augmented capillary length >300µm – n(%)	7 (33)	0	<.001
3. diameter			
mean diameter of capillaries – µm	28.9±0.9	25.7±0.6	.006
enlarged capillaries >25µm – n(%)	4 (19)	0	.007
megacapillary >50µm – n(%)	0	0	NS
4. dystrophy			
capillary branching >15% – n(%)	6 (29)	0	<.001
5. hemorrhage – n(%)			
	0	0	NS
Symptoms of Raynaud:			
n(%) with Raynaud	4 (19)	0	.007
Participants with medications which could induce Raynaud – n(%)	2 (9)	4 (11)	NS
Other causes of Raynaud	0	0	NS
Comorbidities			
Respiratory diseases	2 (9)	6 (17)	NS
Cardiovascular diseases (except high blood pressure)	4 (19)	5 (14)	NS
Myocardial infraction	3 (14)	3(9)	NS
Routine medications – n(%) of patients treated for:			
Blood pressure	7 (33)	13 (37)	NS
Lipid lowering	4 (19)	6 (17)	NS
Smoking – n(%)	9 (43)	18 (51)	NS

Figure legends

Figure 1 Participant flow chart.

Figure 2 Normal capillaroscopy on a control participant (A) and capillaroscopy with dystrophia >15% in a retired worker exposed to VCM for 37 years, with no treatment and no comorbidity, non smoking (B).

For peer review only

1
2
3
4
5
6
7 **The long-term effects of occupational exposure to vinyl chloride monomer**
8
9 **on microcirculation: a cross-sectional study 15 years after retirement**
10

11
12
13
14
15 Vincent Lopez ¹, Alain Chamoux ¹, Marion Tempier ², H el ene Thiel ³, Sylvie Ughetto ⁴,
16
17 Marion Trousselard ⁵, Geraldine Naughton ⁶, Fr ed eric Dutheil ^{1,6,7,*}
18
19

20
21 ¹ Occupational Medicine, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand,
22
23 France
24

25 ² Radiopharmacy, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand, France
26

27 ³ Vascular Medicine, University Hospital CHU G. Montpied, 63000 Clermont-Ferrand,
28
29 France
30

31 ⁴ Department of Medical Information - Clinical research and innovation direction, University
32
33 Hospital CHU G. Montpied, 63000 Clermont-Ferrand, France
34

35 ⁵ Neurophysiology of emotions, ENOP department, CRSSA/IRBA, 38702 La Tronche,
36
37 France
38

39 ⁶ School of Exercise Science, Australian Catholic University, Locked Bag 4115 Fitzroy MDC
40
41 VIC 3065, Australia
42

43 ⁷ Laboratory of Metabolic Adaptations to Exercise in Physiological and Pathological
44
45 conditions (AME2P, EA3533), 63000 Clermont-Ferrand, France
46
47

48 ***Correspondance to** Fr ed eric Dutheil, Occupational Medicine, University Hospital CHU G.
49
50 Montpied, 63000 Clermont-Ferrand, France Tel: +33 6 88 22 48 48. Fax: +33 4 73 27 46 49.
51
52 fred_dutheil@yahoo.fr.
53
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Running Title: Capillaroscopy post-exposure to VCM


Words count for introduction methods results discussion conclusion: ~~2402~~298

Number of tables: 1

Number of figures: 2

Words count for abstract: ~~262~~58

For peer review only



ABSTRACT

Objectives: To assess residual long-term microcirculation abnormalities by capillaroscopy, 15 years after retiring from occupational exposure to vinyl chloride monomer (VCM).

Design: Cross-sectional study.

Setting: Allier, one of the major area of PVC production in France.

Participants: We screened 761 (97% males) retired workers exposed to chemical toxics. Exposure to chemical other than VCM excluded potential participants.

Primary and secondary outcomes measures: These participants underwent a medical examination including a capillaroscopy, symptoms of Raynaud, and comorbidities, as well as a survey to determine exposure time, direct or indirect contact, type of occupation, smoking status and time after exposure. A double blind analysis of capillaroscopic images was done. A control group was matched in age, sex, type of occupation.


Results: 179/761 retired workers were only exposed to VCM at their work, with 21 meeting the inclusion criteria and included. Exposure time was 29.8 ± 1.9 years and time after exposure was 15.9 ± 2.4 years. Retired workers previously exposed to VCM had significantly higher capillaroscopic modifications than 35 controls: enlarged capillaries (19% vs. 0%, $p < .001$), dystrophy (28.6% vs. 0%, $p = .0012$), and augmented length (33% vs. 0%, $p < .001$). Time exposure was linked ($p < .0001$) with enlarged capillaries ($R^2 = .R^2_{\text{adjusted}} = 63\%$), dystrophy ($R^2 = .51$), and capillary length ($R^2 = .36$), $p < .0001$. They also had higher symptoms of Raynaud (19% vs. 0%, $p = .007$) without correlation with capillaroscopic modifications.

Conclusion: Although VCM exposure was already known to affect microcirculation, our study demonstrates residual long term abnormalities following an average of 15 years retirement, with a time-related exposure response. Symptoms of Raynaud, although statistically associated with exposure was not related to capillaroscopic modifications; its origin remains to be determined.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords Exposition, Vinyl chloride monomer, Capillaroscopy, Raynaud

For peer review only



ARTICLE SUMMARY**Article focus**

- Vinyl chloride monomer exposure induces microcirculation abnormalities, which can be diagnosed by capillaroscopy.
- Residual long-term abnormalities following retirement required investigation.

Key messages

- Our results demonstrated residual long-term abnormalities following an average of 15 years retirement, with a time-related exposure response.
- Symptoms of Raynaud, although statistically associated with exposure, was not related to capillaroscopic modifications; its origin remains to be determined.

Strengths and limitations of this study

- The strong points is that this study had a rigorous selection criteria of exclusively VCM exposed participants avoided confounding factor and the focus on retired workers at least 15 years after the end of occupational VCM exposure.
- The main limitation is that pathophysiology of Raynaud after VCM exposure remains unclear.

INTRODUCTION

Vinyl chloride monomer (VCM) is primarily used in the manufacture of plastics and also serves as a raw material in organic synthesis. VCM is an aliphatic hydrocarbon also known as chloroethene. Its polymerization lead to a synthetic resin called polyvinyl chloride, commonly abbreviated PVC. PVC, is the third-most widely produced plastic, after polyethylene and polypropylene.¹ PVC can be made softer and more flexible by the addition of phthalates, and may also replace rubber. Thus, PVC is widely used including: pipes and water distribution, a substitute for painted wood (e.g. window frames, sills, flooring), electrical cable insulation, inflatable products, waterproof clothing (e.g. coats, skiing equipment, shoes), healthcare products (e.g. containers, tubing, catheters), food packaging, dental appliances and vinyl records.¹

Harmless in its polymeric form, workers handling the finished PVC product are perfectly safe.

In contrast, the at-risk phase lies in the manual descaling of autoclaves used for the polymerization where workers can contact it during its monomer state.² The chronic intoxication by gaseous monomer VCM is linked to several symptoms such as:³ asthenia and dizziness,³ Raynaud's syndrome,^{4 5} digestive ulcers with nausea and anorexia,³ systemic symptoms of arthralgia and myalgia³, trophic cutaneous symptoms and sclerosis. It has also been suspected in the onset of acroosteolysis^{4 6 7} and hepatocellular carcinoma.^{8 9} More generally, VCM exposure involves chromosomal aberrations and increased carcinogenic risk.¹⁰ Even if VCM related diseases may have a genetic bases, they are also linked to prolonged occupational VCM exposure.^{5 11}

Scleroderma-like microvascular abnormalities have been also described on exposed workers.¹²⁻¹⁴ The most common and non-invasive means of investigating these abnormalities is capillaroscopy. Widespread identification of individuals most at risk could enable early detection and management strategy.¹⁵ The residual effects of VCM on microcirculation have

1
2
3
4
5
6
7 been shown only once on 15 workers who had ceased their VCM exposure six months prior to
8 testing.¹³ However, residual long-term abnormalities following retirement are unknown. Our
9 hypothesis was higher capillaroscopic abnormalities in the VCM exposed group than in the
10 control group.
11

12
13
14 Therefore, the aim of our cross-sectional study was to investigate residual long-term
15 capillaroscopic abnormalities following retirement, after 15 years without VCM exposure.
16
17
18
19

20 21 22 **METHODS**

23 24 **Participants**

25
26 We enrolled male retired workers exposed to VCM in PVC production. They provided written
27 informed consent. The study was approved by the human ethics committees from Clermont-
28 Ferrand university hospital, France. To be eligible, participants had to be: male (due to male
29 dominance in this workforce), retired, aged over 60 years, with at least a 5-year occupational
30 exposure to VCM, a time after VCM exposure of at least 5 years, and no exposure to
31 chemicals other than VCM. Moreover, participants with diabetes mellitus were also excluded
32 as it may interfere with microcirculation,¹⁶⁻²¹ as well as individuals declaring the use or
33 previous use of treatments which may alter microcirculation.
34
35
36
37
38
39

40
41 Participants responded to a survey to determine exposure time, direct or indirect contact, type
42 of occupation, time after exposure and smoking history. They underwent a medical
43 examination including a capillaroscopy, symptoms of Raynaud, and comorbidities such as
44 pathologies that may interfere with microcirculation (arterial hypertension, dyslipidemia) or
45 pathologies potentially linked with VCM exposure (cardiovascular or respiratory diseases).²²
46
47
48
49
50
51
52
53
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A control group was matched in age, sex, type of occupation. They were recruited via advertisements. Selection criteria for this group also included no occupational or leisure chemical exposure, and no diabetes mellitus.¹⁶⁻²¹

Field Code Changed

Capillaroscopy

A nailfold capillaroscopy was performed on all fingers of each patient, excluding thumbs.²³

Field Code Changed

The nailfold capillaroscopies of the fingers were captured in images and electronically stored.

The same investigator conducted all the capillaroscopies. A double blind analysis of capillaroscopic images was completed on deidentified data.

The outcomes were the five following classical criteria used in capillaroscopy: density, length, diameter, dystrophy and hemorrhage. Criteria for abnormalities were defined as: decreased capillary density <10/mm (avascular zone <7/mm),²⁴ augmented capillary length >300µm,^{24 25} increased capillary diameter >25µm²⁵ (megacapillary >50µm)^{26 27}, and dystrophy was associated with capillary branching >15%.²⁸ Hemorrhage is defined as the microvascular extravasation of the red blood cells linked to the damage of the vessel wall.²⁷

Statistics

Data are presented as mean percentage change and standard deviation (SD).

The main judgment criterion for abnormal microcirculation was the presence of at least one abnormality in capillaroscopy. ~~The most common abnormality is capillary dystrophy.^{25 12-}~~

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

¹⁴Under the assumption of similar proportions of abnormalities as that reported during a VCM exposure,¹²⁻¹⁴ our sample calculation indicated that we would need 27 participants in each of

Formatted: Font: (Default) Times New Roman, 12 pt

Formatted: Font: (Default) Times New Roman, 12 pt

the exposed and non-exposed groups to find a change in probability of 35% (i.e., 40% in exposed versus 5% in non-exposed) for a power of 80% and a two-sided alpha of 5%. When we considered an exposed to non-exposed sample ratio of 1:2, 19 and 38 participants,

Formatted: Font: (Default) Times New Roman, 12 pt

Formatted: Font: (Default) Times New Roman, 12 pt

1
2
3
4
5
6
7 respectively were needed in the exposed and non-exposed groups. Under the assumption of
8
9 0% prevalence in the non-exposed group, sample sizes of 13 exposed and 26 non-exposed
10 were required.

11 ~~Previous data²⁻²⁵ and personal observation on residual long term abnormalities following~~
12 ~~VCM exposure showed that a percentage of dystrophy of approximately 25% was required to~~
13 ~~differentiate between the exposed group and the controls. Using this value as the main~~
14 ~~outcome, we calculated that a sample of 10 participants per group allows a statistical power~~
15 ~~greater than 80% with an alpha level less than 5%.~~

16
17
18
19
20
21
22 Statistical analyses were performed with SPSS software, v19. Correlations were used for
23 inter-observer reliability. The Gaussian distribution for each parameter was assessed by a
24 Shapiro-Wilk test. Comparisons between groups (exposed vs. control) were made through the
25
26 Shapiro-Wilk test. Comparisons between groups (exposed vs. control) were made through the
27
28 usual tests: Chi2 test for categorical variables (or Fisher's exact test where appropriate) and
29
30 Student's t test for quantitative variables (or Kruskal-Wallis if assumptions of normal
31
32 distribution were violated). Significance was accepted for a p-value < 5%. The links between
33
34 continuous variables were analyzed using linear regression. The links between binary and
35
36 continuous variables were analyzed with logistic regression (Nagelkerke R Square).
37
38 Multivariate models were used to predict the relationship between capillary parameters and
39
40 other parameters such as exposure time and time after exposure.
41
42
43
44

45 RESULTS

46 47 48 Participants

49 We screened 761 (97% males) retired workers exposed to chemical toxics from two leading
50
51 enterprises involved in PVC production (n=435 and n=91), as well as participants from many
52
53
54
55

Formatted: Font: (Default) Times New Roman, 12 pt, English (U.S.)

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

1
2
3
4
5
6
7 subcontracting companies (n=235), also known for VCM exposure. The strict selection
8 criteria of exposure only to VCM reduced the sample size to 21 (figure 1).

9
10 Thirty five age-matched controls were also recruited without occupational or leisure time
11 exposure to chemical toxics.
12

13 14 15 16 **Main capillaroscopic outcomes**

17
18 There was no missing data. Inter-rater reliability was confirmed with correlations exceeding
19 0.70 for each parameter. The mean of the values of the 2 investigators is presented in table 1.

20
21 Concerning the qualitative data, when a disagreement occurred, the two observers analyzed
22 again together and requested the opinion of a third expert. The disagreement occurred only for
23 2 decreased capillary density <10/mm, and 1 capillary branching >15%.

24
25 Compared with controls, retired workers previously exposed to VCM had higher
26 capillaroscopic abnormalities: enlarged capillaries (0% vs. 19%, p<.001), dystrophy (0% vs.
27 28.6%, p=.0012) (figure 2), and augmented length (0% vs. 33%, p<.001). The mean length
28 was 15% higher in the exposed group than in controls (p=.020), as well as a 12% greater
29 diameter of capillaries (p=.006) (table 1).
30
31
32
33
34
35
36
37
38

39 **Exposure**

40
41 Exposure time was 29.8±1.9 years and time after exposure was 15.9±2.4 years. Time of
42 exposure to VCM was strongly linked with enlarged capillaries (Nagelkerke R Square
43 approximation of R^2 adjusted = 63%, p<.0001), and with dystrophy (Nagelkerke R Square
44 approximation of 51%, p<.0001), and modestly linked with capillary length expressed as
45 binary ($R^2 = 8%$; p=.031) data (Nagelkerke R Square approximation of 36%, p<.0001) or as
46 quantitative data ($R^2 = 8%$; p=.031) (table 1). Age was not associated with capillaroscopic
47
48
49
50
51
52 abnormalities. No multivariate models improved results from simple regressions.
53
54
55
56
57
58
59
60

Formatted: English (U.S.)

Symptoms of Raynaud

VCM exposed group also had more symptoms of Raynaud (19% vs. 0%, $p=.007$) independent of capillaroscopic modifications (table 1).

Comorbidities and smoking

Neither respiratory nor cardiovascular diseases were associated with VCM exposure. However, we combined both groups to explore potential associations between capillaroscopic parameters and high blood pressure, dyslipidemia, and smoking. Capillary length in participants medicated for arterial hypertension ($n=20/61$) did not differ from participants without hypertension. Participants treated with lipid lowering drugs with dyslipidemia ($n=10/61$) also showed a trend for a higher capillary length than participants without dyslipidemia ($p=.079$). Finally, there were no capillaroscopic difference between smokers and non smokers. However, smokers who had been exposed to VCM tended to have a higher capillary length than non smokers ($p=.073$).

DISCUSSION

Principal findings of the study

Changes in microcirculation persist for at least 15 years following occupational VCM exposure, with a time-related exposure response. Symptoms of Raynaud, although statistically associated with exposure, was not related to pathological capillaroscopic changes.

What the study adds

The microcirculation changes following VCM exposure has been previously shown on 15 workers who ceased their occupational exposure six months prior to testing.¹³ Our study supports these results over a longer period following VCM exposure – 15 years.

The dose responsiveness of VCM exposure and compromised capillarisation is generally,¹³ but not always,¹² reported. Although daily VCM doses may have been more informative, the current study was restricted to years of exposure. Thus, we are limited to describing associations with an exposure time – response rather than a dose-response. Years of exposure is an easy question for physicians to ask of workers during risk assessment protocols.

The absence of changes in microcirculation on less exposed workers²⁹ resulted in a suggestion that a threshold of exposure exists. This finding is supported by previous studies showing that long-term exposure (>8 years) induced greater chromosomal aberrations.^{10 30} Further, not all workers exposed to VCM develop microvascular abnormalities, suggestive of an underlying genetic susceptibility (polymorphism of glutathione S-transferase).^{5 11} A finding that female VCM-exposed workers were more susceptible than males to the risk of increased chromosome damage also reinforced genetic susceptibility theory.³⁰

Comparison with other studies

After 50 years of age, minor dystrophies could alter readability and interpretation of capillaroscopic analyses.³¹ Nevertheless, we controlled this parameter by matching the exposed group and the controls on age and we conducted a double-blind analysis by two experienced readers. Moreover, capillaroscopic abnormalities among workers exposed to VCM in the present study were not influenced by age.¹³ VCM has been suspected of causing respiratory and circulatory diseases.³² However, similar frequencies of these diseases in both groups do not support this hypothesis.

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

1
2
3
4
5
6
7 Diabetes mellitus,¹⁶⁻²¹ high blood pressure,^{18 33-35} dyslipidemia,³⁴ or some
8 comorbidities/medications²² could interfere with microcirculation. In line with previous
9 studies, we showed a diminished capillary length in participants treated for arterial
10 hypertension,^{18 33-35} and a trend for participants treated with lipid lowering drugs.³⁴ Diabetes
11 mellitus was an exclusion criterion and thus, could not interfere with our results. Perhaps due
12 to low numbers of participants, our results failed to support previous findings of compromised
13 microcirculation in people with high blood pressure. The trend for increased capillary length
14 observed in our participants with dyslipidemia could be a response to increased peripheral
15 vascular resistance, in order to maintain their function of metabolic exchange.³⁵ Similarly,
16 smoking could induce a decrease in tissue perfusion,³⁶ and dystrophia.³⁷ We did not observe
17 differences between smokers and non-smokers, with the exception of a trend for abnormal
18 microcirculation among smokers exposed to VCM. The potential of a synergistic effect of
19 tobacco and VCM-exposure warrants further investigations. It should be noted that VCM
20 exposure in the current study was more strongly associated with compromised
21 microcirculation than high blood pressure, dyslipidemia and smoking.

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Previous research into the links between systemic sclerosis and VCM exposure is limited by
single case design³⁸ and somewhat dated analyses of a population exposed to solvents.³⁹ The
broader use of term such as solvents is less specific than the VCM exposure carefully isolated
for investigation in the present study.

A higher prevalence of symptoms of Raynaud has been established in workers with VCM
exposure,³² up to one third of the exposed workers.¹³ The comparison between studies with
different selection criteria and different sample sizes is difficult. There is also the possibility
of selection bias in non randomized recruitment. Within these limitations, our results support
previous data, and extend knowledge by demonstrating the prevalence of symptoms of
Raynaud remained higher at least 15 years following VCM exposure. Furthermore, in the

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

current study, all the participants who suffered from symptoms of Raynaud had never taken medications or suffered from other diseases conducive to Raynaud.

Unanswered questions

Although symptoms of Raynaud are statistically associated with VCM exposure, we could not report a link with capillaroscopic modifications. The pathophysiology of Raynaud's phenomenon remains unknown. There seems to be primary or secondary vascular failure influenced by a hereditary factor.⁴⁰ Decreased perfusion pressure could be secondary to systemic hypotension or be caused by proximal arterial occlusion, influenced by many factors; both vascular and intra vascular, neural, environmental or hereditary.⁴¹ Angiography of the hands of patients exposed to VCM showed occlusions, stenosis and narrowing of distal arteries with the development of collateral circulation.⁴² Lack of statistical power in our study could contribute to the lack of relationship between capillaroscopic changes and symptoms of Raynaud.

Field Code Changed

Field Code Changed

Field Code Changed

Strengths and limitations of study

This study presents some major strengths: a rigorous selection criteria of exclusively VCM exposed participants avoided confounding factors, well-matched controls, a double blind analyses, sufficient number of participants to detect the capillaroscopic differences between groups, the focus on retired workers at least 15 years after the end of occupational VCM exposure. The attendance rate of 30% (53 of 179 individuals exclusively exposed to VCM at work agreed to participate in our study) seems very high compared with other studies⁴³⁻⁴⁷ taking into account their age (75 years), distance from the location of the medical examination (averaging approximately 80 km), and that no financial compensation was offered.

1
2
3
4
5
6
7 There are limitations to this study. ~~The :-a~~ cross-sectional design has limitations; ~~h~~however,
8 proof of concept was important and achieved (with a possibility of longitudinal follow-up). D;
9 ~~d~~ifferences in some but not all capillary outcomes may be explained by a lack of statistical
10 power. T; ~~t~~he results are insufficient to propose guidelines for all workers exposed to VCM.
11 M; ~~m~~ore accurate quantifiable measures of VCM exposure are not available; ~~;~~ however, ; for the
12 purpose of this study we used industry established lists of exposure legally required in France.
13 The ; ~~we combined our knowledge only use a binary~~ pathophysiology of Raynaud after VCM
14 exposure remains unclear. A further limitation may lie in the fact that m; ~~m~~ost of the retired
15 workers exposed to VCM were from the same enterprise; thus, and ~~and~~ potentially more at-risk
16 manufacturing processes remained undetected. Gender specificity may warrant future studies.
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 CONCLUSION

32
33 Although VCM exposure was already known to affect microcirculation, our study
34 demonstrated the potential for residual long-term abnormalities following an average of 15
35 years retirement, with a time exposure – response. Symptoms of Raynaud, although
36 statistically associated with exposure were not associated with capillaroscopic modifications;
37 its origin remains to be determined. Future research could focus on other chemical products
38 which have a similar structure than VCM and more extensive research on type of occupations
39 at-risk of VCM exposure.
40
41
42
43
44
45
46
47
48
49

50 Role of the Funding Source

1
2
3
4
5
6
7 The Occupational Medicine department of CHU G. Montpied, Clermont-Ferrand, France
8 funded this study. No other funding source had a role in the design, conduct, or reporting of
9 the study.
10
11

12 13 14 **Contributors**

15
16 VL has participated as a MD student and principal investigator. FD and AC obtained research
17 funding and generated the intellectual development of the study. FD knew potential exposed
18 workers to VCM. VL, FD, AC and SH contributed to the conception of the protocol. VL, FD
19 and SH made data analysis. VL, FD, MT contributed to manuscript drafting. VL recruited all
20 participants and performed all capillaroscopies. VL and MT completed the double blind
21 analyses of capillaroscopy. FD, AC, VL, GN and MT revised the manuscript. All authors read
22 and approved the final manuscript.
23
24
25
26
27
28
29
30
31

32 **Acknowledgments**

33 Our thanks to Dr George Mnatzaganian Geraldine Naughton for help with statisticsmanuscript
34 English proof reading (-Faculty of Health Sciences, Australian Catholic University, Fitzroy,
35 Victoria, Australia, email: George.Mnatzaganian@acu.edu.au). We also want to acknowledge
36 the “Association of the sick from chemicals” (Association des Malades de la Chimie), 15 Av
37 Albert Poncet 03410 Domerat, France, which helped us recruit the retired workers from VCM
38 exposure.
39
40
41
42
43
44
45
46

47 **REFERENCES**

- 48
49
50
51 1 Allsopp M, Giovanni G. Poly(Vinyl Chloride) *Ullmann's Encyclopedia of Industrial*
52 *Chemistry* 2000.
53 2 Fontana L, Baietto M, Becker F, Catilina P. [Clinical and capillaroscopic study of
54 Raynaud's phenomenon in retired patients previously exposed to vinyl chloride
55 monomer]. *J Mal Vasc* 1995;20:268-73.
56
57
58
59
60

Formatted: English (U.S.)

Field Code Changed

Formatted: No underline, English (U.S.)

Formatted: English (U.S.)

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 3 Veltman G, Lange CE, Juhe S, Stein G, Bachner U. Clinical manifestations and course of vinyl chloride disease. *Ann NY Acad Sci* 1975;246:6-17.
- 4 Harris DK, Adams WG. Acro-osteolysis occurring in men engaged in the polymerization of vinyl chloride. *Br Med J* 1967;3:712-4.
- 5 Fontana L, Marion MJ, Ughetto S, Catilina P. Glutathione S-transferase M1 and GST T1 genetic polymorphisms and Raynaud's phenomenon in French vinyl chloride monomer-exposed workers. *J Hum Genet* 2006;51:879-86.
- 6 Preston BJ, Jones KL, Grainger RG. Clinical aspects of vinyl chloride disease: acro-osteolysis. *Proc R Soc Med* 1976;69:284-6.
- 7 Wilson RH, McCormick WE, Tatum CF, Creech JL. Occupational acroosteolysis. Report of 31 cases. *JAMA* 1967;201:577-81.
- 8 Dragani TA, Zocchetti C. Occupational exposure to vinyl chloride and risk of hepatocellular carcinoma. *Cancer Causes Control* 2008;19:1193-200.
- 9 Mundt KA, Dell LD, Austin RP, Luippold RS, Noess R, Bigelow C. Historical cohort study of 10 109 men in the North American vinyl chloride industry, 1942-72: update of cancer mortality to 31 December 1995. *Occup Environ Med* 2000;57:774-81.
- 10 Kumar AK, Balachandar V, Arun M et al. A Comprehensive Analysis of Plausible Genotoxic Covariates Among Workers of a Polyvinyl Chloride Plant Exposed to Vinyl Chloride Monomer. *Arch Environ Contam Toxicol* 2012.
- 11 Ji F, Zhu S, Sun P, Wang W. [Relationship between genetic polymorphisms of phase I and phase II metabolizing enzymes and DNA damage of workers exposed to vinyl chloride monomer]. *Wei Sheng Yan Jiu* 2009;38:7-11.
- 12 Langauer-Lewowicka H. Nailfolds capillary abnormalities in polyvinyl chloride production workers. *Int Arch Occup Environ Health* 1983;51:337-40.
- 13 Maricq HR, Darke CS, Archibald RM, Leroy EC. In vivo observations of skin capillaries in workers exposed to vinyl chloride. An English-American comparison. *Br J Ind Med* 1978;35:1-7.
- 14 Maricq HR, Johnson MN, Whetstone CL, LeRoy EC. Capillary abnormalities in polyvinyl chloride production workers. Examination by in vivo microscopy. *JAMA* 1976;236:1368-71.
- 15 Kowal-Bielecka O, Bielecki M, Kowal K. Recent advances in the diagnosis and treatment of systemic sclerosis. *Polskie Archiwum Medycyny Wewnetrznej* 2013;123:51-8.
- 16 Pazos-Moura CC, Moura EG, Bouskela E, Torres Filho IP, Breitenbach MM. Nailfold capillaroscopy in non-insulin dependent diabetes mellitus: blood flow velocity during rest and post-occlusive reactive hyperaemia. *Clin Physiol* 1990;10:451-61.
- 17 Iabichella ML, Mariotti R, Nuti M, Balbarini A, Mariani M. [Site specificity of biomicroscopic pattern in diabetic patients]. *Minerva Cardioangiol* 1999;47:619-21.
- 18 Lambova SN, Muller-Ladner U. The specificity of capillaroscopic pattern in connective autoimmune diseases. A comparison with microvascular changes in diseases of social importance: arterial hypertension and diabetes mellitus. *Mod Rheumatol* 2009;19:600-5.
- 19 Vayssairat M, Le Devehat C. [Critical analysis of vascular explorations in diabetic complications]. *J Mal Vasc* 2001;26:122-5.
- 20 Meyer MF, Pfohl M, Schatz H. [Assessment of diabetic alterations of microcirculation by means of capillaroscopy and laser-Doppler anemometry]. *Med Klin (Munich)* 2001;96:71-7.
- 21 Chang CH, Tsai RK, Wu WC, Kuo SL, Yu HS. Use of dynamic capillaroscopy for studying cutaneous microcirculation in patients with diabetes mellitus. *Microvasc Res* 1997;53:121-7.

Formatted: French (France)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 22 Gallucci F, Russo R, Buono R, Acampora R, Madrid E, Uomo G. Indications and results of videocapillaroscopy in clinical practice. *Adv Med Sci* 2008;53:149-57.
- 23 Hern S, Mortimer PS. Visualization of dermal blood vessels--capillaroscopy. *Clin Exp Dermatol* 1999;24:473-8.
- 24 Ingegnoli F, Gualtierotti R, Lubatti C et al. Feasibility of different capillaroscopic measures for identifying nailfold microvascular alterations. *Seminars in Arthritis and Rheumatism* 2009;38:289-95.
- 25 Kabasakal Y, Elvins DM, Ring EF, McHugh NJ. Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. *Ann Rheum Dis* 1996;55:507-12.
- 26 Bhakuni DS, Vasdev V, Garg MK, Narayanan K, Jain R, Mullick G. Nailfold capillaroscopy by digital microscope in an Indian population with systemic sclerosis. *Int J Rheum Dis* 2012;15:95-101.
- 27 Cutolo M, Pizzorni C, Secchi ME, Sulli A. Capillaroscopy. *Best Pract Res Clin Rheumatol* 2008;22:1093-108.
- 28 Jouanny P, Schmidt C, Feldmann L, Schmitt J. [Focus on a quick reading of nailfold capillaroscopy]. *Journal des Maladies Vasculaires* 1994;19:206-9.
- 29 Przybylowski J, Podolecki A, Laks L et al. [Health status of workers in polyvinyl chloride processing plants. I. Evaluation of occupational exposure. Subjective and capillaroscopy studies. Conduction velocity in the motor nerves]. *Med Pr* 1983;34:385-96.
- 30 Jiao J, Feng NN, Li Y et al. Estimation of a Safe Level for Occupational Exposure to Vinyl Chloride Using a Benchmark Dose Method in Central China. *J Occup Health* 2012.
- 31 Carpentier PH. New techniques for clinical assessment of the peripheral microcirculation. *Drugs* 1999;59 Spec No:17-22.
- 32 Laplanche A, Clavel F, Contassot JC, Lanouziere C. Exposure to vinyl chloride monomer: report on a cohort study. *Br J Ind Med* 1987;44:711-5.
- 33 Prasad A, Dunnill GS, Mortimer PS, MacGregor GA. Capillary rarefaction in the forearm skin in essential hypertension. *J Hypertens* 1995;13:265-8.
- 34 Bonacci E, Santacroce N, D'Amico N, Mattace R. Nail-fold capillaroscopy in the study of microcirculation in elderly hypertensive patients. *Arch Gerontol Geriatr* 1996;22 Suppl 1:79-83.
- 35 Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Structural skin capillary rarefaction in essential hypertension. *Hypertension* 1999;33:998-1001.
- 36 Lehr HA. Microcirculatory dysfunction induced by cigarette smoking. *Microcirculation* 2000;7:367-84.
- 37 Lova RM, Miniati B, Macchi C et al. Morphologic changes in the microcirculation induced by chronic smoking habit: a videocapillaroscopic study on the human labial mucosa. *Am Heart J* 2002;143:658.
- 38 Betta A, Tommasini M, Bovenzi M, Barbone F, Versini W, Romeo L. [Scleroderma and occupational factors: a case-control study and analysis of literature]. *Medicina del Lavoro* 1994;85:496-506.
- 39 Ostlere LS, Harris D, Buckley C, Black C, Rustin MH. Atypical systemic sclerosis following exposure to vinyl chloride monomer. A case report and review of the cutaneous aspects of vinyl chloride disease. *Clinical and Experimental Dermatology* 1992;17:208-10.
- 40 Block JA, Sequeira W. Raynaud's phenomenon. *Lancet* 2001;357:2042-8.
- 41 Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. *Nat Rev Rheumatol* 2012;8:469-79.

Formatted: French (France)

Formatted: French (France)

Formatted: French (France)


Formatted: French (France)

- 1
2
3
4
5
6
7 42 Koischwitz D, Marsteller HJ, Lackner K, Brecht G, Brecht T. [Changes in the arteries
8 in the hand and fingers due to vinyl chloride exposure (author's transl)]. *Rofo*
9 1980;132:62-8.
- 10 43 Dutheil F, Kelly C, Biat I et al. [Relation between the level of knowledge and the rate
11 of vaccination against the flu virus among the staff of the Clermont-Ferrand
12 University hospital]. *Med Mal Infect* 2008;38:586-94.
- 13 44 Chiew M, Weber MF, Egger S, Sitas F. A cross-sectional exploration of smoking
14 status and social interaction in a large population-based Australian cohort. *Social
15 Science and Medicine* 2012;75:77-86.
- 16 45 Penforis A, San-Galli F, Cimino L, Huet D. Current insulin therapy in patients with
17 type 2 diabetes: results of the ADHOC survey in France. *Diabetes and Metabolism*
18 2011;37:440-5.
- 19 46 Heinavaara S, Tokola K, Kurttio P, Auvinen A. Validation of exposure assessment
20 and assessment of recruitment methods for a prospective cohort study of mobile phone
21 users (COSMOS) in Finland: a pilot study. *Environ Health* 2011;10:14.
- 22 47 Eriksen L, Gronbaek M, Helge JW, Tolstrup JS, Curtis T. The Danish Health
23 Examination Survey 2007-2008 (DANHES 2007-2008). *Scand J Public Health*
24 2011;39:203-11.
- 25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Characteristics of participants, exposure to VCM and capillaroscopic outcomes.


	Retired from exposure to VCM (n=21)	Controls (n=40)	p- value
Age – years	74.4±2.9	76.3±3.2	NS
type of occupation: blue collar workers – “manual”	100%	100%	NS
Exposure to VCM:			
direct contact with VCM	100%	0	<.001
exposure time – years	29.8±1.9	0	<.001
time after exposure – years	15.9±2.4	-	-
Main capillaroscopic outcomes:			
1. density			
mean density – mm	8.6±0.4	8.8±0.3	NS
decreased capillary density <10/mm – n (%)	9 (43)	16 (46)	NS
avascular zone <7/mm – n(%)	0	0	NS
2. length			
mean length – μm	291±14	254±9	.020
augmented capillary length >300μm – n(%)	7 (33)	0	<.001
3. diameter			
mean diameter of capillaries – μm	28.9±0.9	25.7±0.6	.006
enlarged capillaries >25μm – n(%)	4 (19)	0	<.007 ‡
megacapillary >50μm – n(%)	0	0	NS
4. dystrophy			
capillary branching >15% – n(%)	6 (29)	0	<.001
5. hemorrhage – n(%)			
	0	0	NS
Symptoms of Raynaud:			
n(%) with Raynaud	4 (19)	0	.007
Participants with medications which could induce Raynaud – n(%)	2 (9)	4 (11)	NS
Other causes of Raynaud	0	0	NS
Comorbidities			
Respiratory diseases	2 (9)	6 (17)	NS
Cardiovascular diseases (except high blood pressure)	4 (19)	5 (14)	NS
Myocardial infraction	3 (14)	3(9)	NS
Routine medications – n(%) of patients treated for:			
Blood pressure	7 (33)	13 (37)	NS
Lipid lowering	4 (19)	6 (17)	NS
Smoking – n(%)	9 (43)	18 (51)	NS

Figure 1 Participant flow chart.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2 Normal capillaroscopy on a control participant (A) and capillaroscopy with dystrophia >15% in a retired worker exposed to VCM for 37 years, with no treatment and no comorbidity, non smoking (B).



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	19 (figure 1)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-9
		(b) Describe any methods used to examine subgroups and interactions	8-9
		(c) Explain how missing data were addressed	8-9
		(d) If applicable, describe analytical methods taking account of sampling strategy	8-9
		(e) Describe any sensitivity analyses	8-9
Results			


Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	19 (figure 1)
		(b) Give reasons for non-participation at each stage	19 (figure 1)
		(c) Consider use of a flow diagram	19 (figure 1)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7;9; 19 (figure 1)
		(b) Indicate number of participants with missing data for each variable of interest	9
Outcome data	15*	Report numbers of outcome events or summary measures	9-10; 19 (figure 1)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10; 19 (figure 1)
		(b) Report category boundaries when continuous variables were categorized	9-10; 19 (figure 1)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-10
Discussion			
Key results	18	Summarise key results with reference to study objectives	11-13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-13
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1 Participant flow chart.




.....
.....

90x116mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2 Normal capillaroscopy on a control participant (A) and capillaroscopy with dystrophia >15% in a retired worker exposed to VCM for 37 years, with no treatment and no comorbidity, non smoking (B).



182x90mm (300 x 300 DPI)

er review only